

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re

ACORDA THERAPEUTICS, INC., *et al.*,¹

Debtors.

Chapter 11

Case No. 24-22284 (DSJ)

(Jointly Administered)

AFFIDAVIT OF SERVICE

I, Ali Hamza, depose and say that I am employed by Kroll Restructuring Administration LLC (“**Kroll**”), the claims and noticing agent for the Debtors in the above-captioned chapter 11 cases.

On May 1, 2024, at my direction and under my supervision, employees of Kroll caused the following document to be served by the method set forth on the Master Service List attached hereto as **Exhibit A**:

- Notice to Contract Parties to Potentially Assumed Executory Contracts, a copy of which is attached hereto as **Exhibit B** (the “**Cure Notice**”)

On May 2, 2024, at my direction and under my supervision, employees of Kroll caused the Cure Notice to be served via overnight mail on the Assumption Counterparties Service List attached hereto as **Exhibit C**.

On May 6, 2024, at my direction and under my supervision, employees of Kroll caused the Cure Notice to be served via email on (i) (ADRID: 28874124) Saul Ewing LLP, Attn: Luke Murley, Partner, at Luke.murley@saul.com; (ii) (ADRID: 28874125) Eversana Life Science Services, Attn: Tamra Zimay, at Tamra.zimay@eversana.com; and (iii) (ADRID: 28876406) Caremark, L.L.C., Attn: Emil P. Khatchatourian, Geoff Goodman, Joseph S. Harper at Ekhatourian@foley.com, Jharper@foley.com, and Ggoodman@foley.com.

[Remainder of page intentionally left blank]

¹ The Debtors in these chapter 11 cases, along with the last four (4) digits of each Debtor’s federal tax identification number, are: Acorda Therapeutics, Inc. (1168), Civitas Therapeutics, Inc. (2814), Biotie Therapies, LLC (2149), Biotie Therapies AG (N/A), Neuronex, Inc. (5094), and Acorda Therapeutics Limited (N/A). For the purposes of these chapter 11 cases, the address for the Debtors is: 2 Blue Hill Plaza, 3rd Floor, Pearl River, New York 10965.

Dated: May 13, 2024

/s/ Ali Hamza

Ali Hamza

State of New York
County of New York

Subscribed and sworn (or affirmed) to me on May 13, 2024, by Ali Hamza, proved to me on the bases of satisfactory evidence to be the person who executed this affidavit.

/s/ OLEG BITMAN

Notary Public, State of New York

No. 01BI6339574

Qualified in New York County

Commission Expires April 4, 2028

Exhibit A

Exhibit A
Master Service List
Served as set forth below

DESCRIPTION	NAME	ADDRESS	EMAIL	METHOD OF SERVICE
DEBTORS	ACORDA THERAPEUTICS, INC.	ATTN: NIEL BELLOFF 2 BLUE HILL PLAZA 3RD FLOOR PEARL RIVER NY 10965	NBELLOFF@ACORDA.COM MGESSER@ACORDA.COM	Email
TOP 30 UNSECURED CREDITORS	APOLLO RX LLC	ATTN: DAN WALLENBERG, CHIEF COMMERCIAL OFFICER 150 N RIVERSIDE PLAZA SUITE 3400 CHICAGO IL 60606	DWALLENBERG@NOVOSGROWTH.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	AXIOM GLOBAL INC.	ATTN: LYNN LAPIERRE 75 SPRING STREET FLOOR 8 NEW YORK NY 10012	HELLO@AXIOMGLOBAL.COM	First Class Mail and Email
PROPOSED COUNSEL TO THE DEBTORS AND DEBTORS IN POSSESSION	BAKER & MCKENZIE LLP	ATTN: BLAIRE CAHN 452 FIFTH AVENUE NEW YORK NY 10018	BLAIRE.CAHN@BAKERMCKENZIE.COM	Email
PROPOSED COUNSEL TO THE DEBTORS AND DEBTORS IN POSSESSION	BAKER & MCKENZIE LLP	ATTN: JON R. DODD 1111 BRICKELL AVENUE 10TH FLOOR MIAMI FL 33131	JOHN.DODD@BAKERMCKENZIE.COM	Email
COUNSEL TO ORACLE AMERICA INC.	BUCHALTER, A PROFESSIONAL CORPORATION	ATTN: SHAWN M. CHRISTIANSON 425 MARKET STREET SUITE 2900 SAN FRANCISCO CA 94105	SCHRISTIANSON@BUCHALTER.COM	Email
TOP 30 UNSECURED CREDITORS	CAREMARK L.L.C.	ATTN: BRADLEY KRUK, MANAGER, TRADE SERVICES 2211 SANDERS ROAD 8TH FLOOR NORTHBROOK IL 60062	BRADLEY.KRUK@CVSHEALTH.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	CATALENT MASSACHUSETTS LLC	ATTN: GENERAL COUNSEL (LEGAL DEPARTMENT) 14 SCHOOLHOUSE ROAD SOMERSET NJ 08873	GENSCOUNS@CATALENT.COM	First Class Mail and Email
UNITED STATES BANKRUPTCY COURT FOR THE SOUTHERN DISTRICT OF NEW YORK	CHAMBERS OF HONORABLE JUDGE DAVID S. JONES	ACORDA CHAMBERS COPY US BANKRUPTCY COURT SDNY ONE BOWLING GREEN NEW YORK NY 10004-1408		First Class Mail
COMMONWEALTH OF PUERTO RICO	COMMONWEALTH OF PUERTO RICO	ATTENTION BANKRUPTCY DEPT APARTADO 9020192 SAN JUAN PR 00902-0192		First Class Mail
TOP 30 UNSECURED CREDITORS	COMPUTER PACKAGES INC.	ATTN: ANNA SARKISSAIN 11 N. WASHINGTON STREET SUITE 300 ROCKVILLE MD 20850	ASARKISSIAN@COMPUTERPACKAGES.COM	First Class Mail and Email
COUNSEL TO BIOGEN IDEC INTERNATIONAL GMBH	CRAVATH, SWAINE & MOORE LLP	ATTN: PAUL ZUMBRO, ALEXANDER GERTEN WORLDWIDE PLAZA 825 EIGHTH AVENUE NEW YORK NY 10019	PZUMBRO@CRAVATH.COM AGERTEN@CRAVATH.COM	Email
TOP 30 UNSECURED CREDITORS	DELAWARE DEPARTMENT OF FINANCE	OFFICE OF UNCLAIMED PROPERTY ATTN: OFFICE OF UNCLAIMED PROPERTY CARVEL STATE OFFICE BLDG 820 N FRENCH ST. WILMINGTON DE 19801	ESCHEAT.CLAIMQUESTIONS@DELAWARE.GOV	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	DELAWARE DEPARTMENT OF FINANCE			First Class Mail
TOP 30 UNSECURED CREDITORS	DLA PIPER LLP (US)	ATTN: MICHAEL SITZMAN, PARTNER LOCKBOX SERVICES 780528 MAC Y1372-045, 401 MARKET STREET PHILADELPHIA PA 19106	ACCT-ARINQUIRIES@US.DLAPIPER.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	DLA PIPER LLP (US)	ATTN: MICHAEL SITZMAN, PARTNER PO BOX 780528 PHILADELPHIA PA 19178-0528	MICHAEL.SITZMAN@US.DLAPIPER.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	ELMORE PATENT LAW GROUP. PC	ATTN: CAROLYN ELMORE, PRESIDENT 484 GROTON ROAD WESTFORD MA 01886	CELMORE@ELMOREPATENTS.COM	First Class Mail and Email

Exhibit A
Master Service List
Served as set forth below

DESCRIPTION	NAME	ADDRESS	EMAIL	METHOD OF SERVICE
TOP 30 UNSECURED CREDITORS	EUROPEAN MEDICINES AGENCY	ATTN: PRESIDENT OR GENERAL COUNSEL DOMENICO SCARLATTILAN 6 AMSTERDAM 1083HS THE NETHERLANDS	ACCOUNTSRECEIVABLE@EMA.EUROPA.EU	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	EVERSANA LIFE SCIENCE SERVICES	ATTN: TAMMY WHITE, ASSOCIATE DIRECTOR, MEDICAL COMMUNICATIONS 24740 NETWORK PLACE CHICAGO IL 60673-1247	ACCOUNTING-MC@EVERSANA.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	EVERSOURCE	ATTN: JOSEPH R. NOLAN, JR., CEO 56 PROSPECT ST HARTFORD CT 06103	MELISSA.CAMERON@EVERSOURCE.COM MATTHEW.FALLON@EVERSOURCE.COM	First Class Mail and Email
FINANCIAL INDUSTRY REGULATORY AUTHORITY	FINANCIAL INDUSTRY REGULATORY AUTHORITY	ATTN: BANKRUPTCY DEPARTMENT 1700 K STREET, NW WASHINGTON DC 20006	OTC.BANKRUPTCIES@FINRA.ORG	Email
TOP 30 UNSECURED CREDITORS	FORTREA PATIENT ACCESS	ATTN: HIMA INGUVA, HEAD OF INVESTOR RELATIONS 8 MOORE DRIVE DURHAM NC 27703	INVESTORS@FORTREA.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	FORTREA PATIENT ACCESS	ATTN: LILLIAN STEINBOCK, EXECUTIVE DIRECTOR PATIENT SUPPORT SOLUTIONS PO BOX 931364 ATLANTA GA 31193-1364	LILLIAN.STEINBOCK@FORTREA.COM	First Class Mail and Email
COUNSEL TO MERZ PHARMACEUTICALS, LLC & STALKING HORSE BIDDER	FRESHFIELDS BRUCKHAUS DERINGER US LLP	ATTN: SCOTT D. TALMADGE, ALEXANDER A. RICH, ALI M. MUFFENBIER, ELLEN S. LAWRENCE 3 WORLD TRADE CENTER 175 GREENWICH STREET, 51ST FLOOR NEW YORK NY 10007	SCOTT.TALMADGE@FRESHFIELDS.COM ALEXANDER.RICH@FRESHFIELDS.COM ALI.MUFFENBIER@FRESHFIELDS.COM ELLEN.LAWRENCE@FRESHFIELDS.COM	Email
TOP 30 UNSECURED CREDITORS	INDEGENE INC.	ATTN: MATT SKORONSKI, SR DIRECTOR 150 COLLEGE RD W PRINCETON NJ 08540		First Class Mail
TOP 30 UNSECURED CREDITORS	INDEGENE INC.	ATTN: MATT SKORONSKI, SR DIRECTOR PO BOX 69091 BALTIMORE MD 21264	MATTHEW.SKORONSKI@INDEGENE.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	INSIGHT	ATTN: ROB MCCONNELL, SENIOR SALES ACCOUNT MANAGER 2701 E INSIGHT WAY CHANDLER AZ 85286	ACH@INSIGHT.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	INSIGHT	ATTN: ROB MCCONNELL, SENIOR SALES ACCOUNT MANAGER PO BOX 731069 DALLAS TX 75373-1069	ROB.MCCONNELL@INSIGHT.COM	First Class Mail and Email
IRS INSOLVENCY SECTION	INTERNAL REVENUE SERVICE	CENTRALIZED INSOLVENCY OPERATION 2970 MARKET STREET MAIL STOP 5 Q30 133 PHILADELPHIA PA 19104-5016	MIMI.M.WONG@IRSCOUNSEL.TREAS.GOV	First Class Mail and Email
IRS INSOLVENCY SECTION	INTERNAL REVENUE SERVICE	CENTRALIZED INSOLVENCY OPERATION P.O. BOX 7346 PHILADELPHIA PA 19101-7346	MIMI.M.WONG@IRSCOUNSEL.TREAS.GOV	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	IQVIA INC.	ATTN: KERRI JOSEPH, SENIOR VP INVESTOR RELATIONS & TREASURY 83 WOOSTER HEIGHTS ROAD DANBURY CT 06810	IR@IQVIA.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	IQVIA INC.	ATTN: SYLWIA SZYMANSKI, FINANCE MANAGER PO BOX 8500-784290 PHILADELPHIA PA 19178-4290	SYLWIA.SZYMANSKI@IQVIA.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	JONES DAY	ATTN: ADRIANE ANTLER 250 VESEY STREET NEW YORK NY 10281-1047	AMANTLER@JONESDAY.COM	First Class Mail and Email
COUNSEL TO PRIMEVIGILANCE	KILPATRICK TOWNSEND & STOACKTON LLP	ATTN: DAVID M. POSNER, GIANFRANCO FINIZIO, KELLY E. MOYNIHAN THE GRACE BUILDING 1114 AVENUE OF THE AMERICAS NEW YORK NY 10036	DPOSNER@KTSLAW.COM GFINIZIO@KTSLAW.COM KMOYNIHAN@KTSLAW.COM	Email
COUNSEL TO THE DIP ADMINISTRATIVE AGENT, GLAS TRUST COMPANY LLC	KING & SPALDING	ATTN: MATTHEW WARREN AND LINDSEY HENRIKSON 110 N WACKER DRIVE SUITE 3800 CHICAGO IL 60606	MWARREN@KSLAW.COM LHENRIKSON@KSLAW.COM	First Class Mail and Email
COUNSEL TO THE AD HOC NOTEHOLDER GROUP	KING & SPALDING LLP	ATTN: MATTHEW L. WARREN, LINDSEY HENRIKSON, VALERIE ELIASSEN, AMY CHO 110 N. WACKER DRIVE SUITE 3800 CHICAGO IL 60606	MWARREN@KSLAW.COM LHENRIKSON@KSLAW.COM VELIASSEN@KSLAW.COM ACHO@KSLAW.COM	Email

Exhibit A
Master Service List
Served as set forth below

DESCRIPTION	NAME	ADDRESS	EMAIL	METHOD OF SERVICE
COUNSEL TO CATALENT MASSACHUSETTS LLC	LOWENSTEIN SANDLER LLP	ATTN: JEFFREY L. COHEN, ESQ. 1251 AVENUE OF THE AMERICAS NEW YORK NY 10020	JCOHEN@LOWENSTEIN.COM	Email
COUNSEL TO CATALENT MASSACHUSETTS LLC	LOWENSTEIN SANDLER LLP	ATTN: MICHAEL PAPANDREA, ESQ. ONE LOWENSTEIN DRIVE ROSELAND NJ 07068	MPAPANDREA@LOWENSTEIN.COM	Email
COUNSEL TO THE OFFICIAL COMMITTEE OF UNSECURED CREDITORS	MCDERMOTT WILL & EMERY LLP	ATTN: DARREN AZMAN, KRISTIN K. GOING, STACY LUTKUS, DANIEL THOMSON ONE VANDERBILT AVENUE NEW YORK NY 10017-3852	DAZMAN@MWE.COM KGOING@MWE.COM SALUTKUS@MWE.COM DTHOMSON@MWE.COM	Email
NATIONAL ASSOCIATION OF ATTORNEYS GENERAL	NATIONAL ASSOCIATION OF ATTORNEYS GENERAL	ATTN: KAREN CORDRY 1850 M ST., NW 12TH FLOOR WASHINGTON DC 20036	KCORDRY@NAAG.ORG	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	NSIGHT DRIVEN COMMUNICATIONS LLC	ATTN: JOHN TENAGLIA, PARTNER 379 WEST BROADWAY SUITE 550 NEW YORK NY 10012	JOHN.TENAGLIA@WEAREMOONRABBIT.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	NYS OFFICE OF THE STATE COMPTROLLER	ATTN: OFFICE OF THE STATE COMPTROLLER OFFICE OF UNCLAIMED FUNDS REMITTANCE CONTROL, 110 STATE STREET 2ND FLOOR ALBANY NY 12236	CONTACTUS@OSC.NY.GOV	First Class Mail and Email
OFFICE OF THE ATTORNEY GENERAL GUAM	OFFICE OF THE ATTORNEY GENERAL GUAM	ATTN: BANKRUPTCY DEPT 590 S. MARINE CORPS DR., SUITE 901 TAMUNING GU 96913		First Class Mail
TOP 30 UNSECURED CREDITORS	PRIME VIGILANCE LTD	ATTN: RICHARD O'HARA, SENIOR MEDICAL INFORMATION ASSOCIATE 26-28 FREDERICK SANGER ROAD. SURREY RESEARCH PARK, GUILDFORD SURREY GU2 7YD UNITED KINGDOM	ACCOUNTS.RECEIVABLEPV@PRIMEVIGILANCE.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	PRINT COTTAGE	ATTN: JAMES ALTADONNA, PRESIDENT 54 MARKET STREET ONANCOCK VA 23417	JALTADONNA@AOL.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	RESEARCH CATALYST LLC	ATTN: MELISSA OVERBAUGH, DIRECTOR 701 E. HAMPDEN AVENUE SUITE 510 ENGLEWOOD CO 80113	MOVERBAUGH@RESEARCHCAT.COM	First Class Mail and Email
COUNSEL TO ESTEVE PHARMACEUTICALS GMBH AND ESTEVE PHARMACEUTICALS, S.A.	ROPES & GRAY LLP	ATTN: MARK R. SOMERSTEIN 1211 AVENUE OF THE AMERICAS NEW YORK NY 10036-8704	MARK.SOMERSTEIN@ROPESGRAY.COM	Email
SECURITIES AND EXCHANGE COMMISSION - HEADQUARTERS	SECURITIES & EXCHANGE COMMISSION	ATTN: SECRETARY OF THE TREASURY 100 F STREET, NE WASHINGTON DC 20549	SECBANKRUPTCY@SEC.GOV NYROBANKRUPTCY@SEC.GOV	First Class Mail and Email
SECURITIES AND EXCHANGE COMMISSION - REGIONAL OFFICE	SECURITIES & EXCHANGE COMMISSION - NY OFFICE	ATTN: BANKRUPTCY DEPARTMENT BROOKFIELD PLACE 200 VESEY STREET, SUITE 400 NEW YORK NY 10281-1022	BANKRUPTCYNOTICESCHR@SEC.GOV	First Class Mail and Email
SECURITIES AND EXCHANGE COMMISSION - REGIONAL OFFICE	SECURITIES & EXCHANGE COMMISSION - PHILADELPHIA OFFICE	ATTN: BANKRUPTCY DEPT ONE PENN CENTER 1617 JFK BLVD, STE 520 PHILADELPHIA PA 19103	SECBANKRUPTCY@SEC.GOV	First Class Mail and Email
COUNSEL TO WILMINGTON TRUST, NATIONAL ASSOCIATION	SEWARD & KISSEL LLP	ATTN: JOHN R. ASHMEAD, GREGG S. BATEMAN, CATHERINE V. LOTEMPPIO, ANDREW J. MATOTT ONE BATTERY PARK PLAZA NEW YORK NY 10004	ASHMEAD@SEWKIS.COM BATEMAN@SEWKIS.COM LOTEMPPIO@SEWKIS.COM MATOTT@SEWKIS.COM	Email
TOP 30 UNSECURED CREDITORS	SHARP CORPORATION	ATTN: BARBARA OST, VICE PRESIDENT 7451 KEEBLER WAY ALLENTOWN PA 18106	BARBARA.OST@SHARPSERVICES.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	SLATE360 INC.	ATTN: SHAWN DONNELLY, PARTNER 6628 SKY POINTE DRIVE SUITE 120 LAS VEGAS NV 89131	ACCOUNTING@SLATE360INC.COM	First Class Mail and Email

Exhibit A
Master Service List
Served as set forth below

DESCRIPTION	NAME	ADDRESS	EMAIL	METHOD OF SERVICE
TOP 30 UNSECURED CREDITORS	SMC LTD.	ATTN: CONTRACT ADMINISTRATION 330 SMC DRIVE SOMERSET WI 54025	SMC.AR@SMCLTD.COM	First Class Mail and Email
COUNSEL TO PASO MILAK, JOHN FEISTHAMEL AND ADAM ARREDONO	SPENCER FAN LLP	ATTN: ANGUS DWYER 1000 WALNUT SUITE 1400 KANSAS CITY MO 64106	ADWYER@SPENCERFANE.COM	Email
COUNSEL TO PASO MILAK, JOHN FEISTHAMEL AND ADAM ARREDONO	SPENCER FAN LLP	ATTN: GERRIT M. PRONSKE, ZACHARY R.G. FAIRLIE 5700 GRANITE PARKWAY SUITE 650 PLANO TX 75024	GPRONSKE@SPENCERFANE.COM ZFAIRLIE@SPENCERFANE.COM	Email
STATE OF ALABAMA ATTORNEY GENERAL	STATE OF ALABAMA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT P.O. BOX 300152 MONTGOMERY AL 36130-0152		First Class Mail
STATE OF ALASKA ATTORNEY GENERAL	STATE OF ALASKA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT P.O. BOX 110300 JUNEAU AK 99811-0300	ATTORNEY.GENERAL@ALASKA.GOV	First Class Mail and Email
STATE OF ARIZONA ATTORNEY GENERAL	STATE OF ARIZONA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 2005 N CENTRAL AVE PHOENIX AZ 85004-2926	AGINFO@AZAG.GOV	First Class Mail and Email
STATE OF ARKANSAS ATTORNEY GENERAL	STATE OF ARKANSAS ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 323 CENTER ST. SUITE 200 LITTLE ROCK AR 72201-2610		First Class Mail
STATE OF CALIFORNIA ATTORNEY GENERAL	STATE OF CALIFORNIA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT P.O. BOX 944255 SACRAMENTO CA 94244-2550	BANKRUPTCY@COAG.GOV	First Class Mail and Email
STATE OF COLORADO ATTORNEY GENERAL	STATE OF COLORADO ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT RALPH L. CARR COLORADO JUDICIAL CENTER 1300 BROADWAY, 10TH FLOOR DENVER CO 80203		First Class Mail
STATE OF CONNECTICUT ATTORNEY GENERAL	STATE OF CONNECTICUT ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 165 CAPITOL AVENUE HARTFORD CT 06106	ATTORNEY.GENERAL@CT.GOV DENISE.MONDELL@CT.GOV	First Class Mail and Email
STATE OF DELAWARE ATTORNEY GENERAL	STATE OF DELAWARE ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT CARVEL STATE OFFICE BLDG. 820 N. FRENCH ST. WILMINGTON DE 19801	ATTORNEY.GENERAL@STATE.DE.US ATTORNEY.GENERAL@DELAWARE.GOV	First Class Mail and Email
STATE OF FLORIDA ATTORNEY GENERAL	STATE OF FLORIDA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT THE CAPITOL, PL 01 TALLAHASSEE FL 32399-1050		First Class Mail
STATE OF GEORGIA ATTORNEY GENERAL	STATE OF GEORGIA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 40 CAPITAL SQUARE, SW ATLANTA GA 30334-1300		First Class Mail
STATE OF HAWAII ATTORNEY GENERAL	STATE OF HAWAII ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 425 QUEEN ST. HONOLULU HI 96813	HAWAIIAG@HAWAII.GOV	First Class Mail and Email
STATE OF IDAHO ATTORNEY GENERAL	STATE OF IDAHO ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 700 W. JEFFERSON STREET P.O. BOX 83720 BOISE ID 83720-1000		First Class Mail
STATE OF ILLINOIS ATTORNEY GENERAL	STATE OF ILLINOIS ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 100 WEST RANDOLPH STREET CHICAGO IL 60601	WEBMASTER@ATG.STATE.IL.US	First Class Mail and Email
STATE OF INDIANA ATTORNEY GENERAL	STATE OF INDIANA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT INDIANA GOVERNMENT CENTER SOUTH 302 W. WASHINGTON ST., 5TH FLOOR INDIANAPOLIS IN 46204	INFO@ATG.IN.GOV	First Class Mail and Email
STATE OF IOWA ATTORNEY GENERAL	STATE OF IOWA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 1305 E. WALNUT STREET DES MOINES IA 50319	WEBTEAM@AG.IOWA.GOV	First Class Mail and Email

Exhibit A
Master Service List
Served as set forth below

DESCRIPTION	NAME	ADDRESS	EMAIL	METHOD OF SERVICE
STATE OF KANSAS ATTORNEY GENERAL	STATE OF KANSAS ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 120 SW 10TH AVE., 2ND FLOOR TOPEKA KS 66612-1597		First Class Mail
STATE OF KENTUCKY ATTORNEY GENERAL	STATE OF KENTUCKY ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 700 CAPITOL AVENUE, SUITE 118 FRANKFORT KY 40601		First Class Mail
STATE OF LOUISIANA ATTORNEY GENERAL	STATE OF LOUISIANA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT P.O. BOX 94095 BATON ROUGE LA 70804-4095	CONSUMERINFO@AG.STATE.LA.US	First Class Mail and Email
STATE OF MAINE ATTORNEY GENERAL	STATE OF MAINE ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 6 STATE HOUSE STATION AUGUSTA ME 04333-0000		First Class Mail
STATE OF MARYLAND ATTORNEY GENERAL	STATE OF MARYLAND ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 200 ST. PAUL PLACE BALTIMORE MD 21202-2202	OAG@OAG.STATE.MD.US	First Class Mail and Email
STATE OF MASSACHUSETTS ATTORNEY GENERAL	STATE OF MASSACHUSETTS ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT ONE ASHBURTON PLACE BOSTON MA 02108-1698	AGO@STATE.MA.US	First Class Mail and Email
STATE OF MICHIGAN ATTORNEY GENERAL	STATE OF MICHIGAN ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT G. MENNEN WILLIAMS BUILDING, 7TH FLOOR 525 W. OTTAWA ST., P.O. BOX 30212 LANSING MI 48909-0212	MIAG@MICHIGAN.GOV	First Class Mail and Email
STATE OF MINNESOTA ATTORNEY GENERAL	STATE OF MINNESOTA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 1400 BREMER TOWER 445 MINNESOTA STREET ST. PAUL MN 55101-2131		First Class Mail
STATE OF MISSISSIPPI ATTORNEY GENERAL	STATE OF MISSISSIPPI ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT WALTER SILLERS BUILDING 550 HIGH STREET, SUITE 1200, P.O. BOX 220 JACKSON MS 39201		First Class Mail
STATE OF MISSOURI ATTORNEY GENERAL	STATE OF MISSOURI ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT SUPREME COURT BUILDING 207 W. HIGH ST. JEFFERSON CITY MO 65102	ATTORNEY.GENERAL@AGO.MO.GOV	First Class Mail and Email
STATE OF MONTANA ATTORNEY GENERAL	STATE OF MONTANA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 215 N SANDERS, THIRD FLOOR PO BOX 201401 HELENA MT 59620-1401	CONTACTDOJ@MT.GOV	First Class Mail and Email
STATE OF NEBRASKA ATTORNEY GENERAL	STATE OF NEBRASKA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 2115 STATE CAPITOL 2ND FL, RM 2115 LINCOLN NE 68509-8920	AGO.INFO.HELP@NEBRASKA.GOV	First Class Mail and Email
STATE OF NEVADA ATTORNEY GENERAL	STATE OF NEVADA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 100 NORTH CARSON STREET CARSON CITY NV 89701	AGINFO@AG.NV.GOV	First Class Mail and Email
STATE OF NEW HAMPSHIRE ATTORNEY GENERAL	STATE OF NEW HAMPSHIRE ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 33 CAPITOL ST. CONCORD NH 03301-0000	ATTORNEYGENERAL@DOJ.NH.GOV	First Class Mail and Email
STATE OF NEW JERSEY ATTORNEY GENERAL	STATE OF NEW JERSEY ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT RJ HUGHES JUSTICE COMPLEX 25 MARKET STREET, P.O. BOX 080 TRENTON NJ 08625-0080		First Class Mail
STATE OF NEW MEXICO ATTORNEY GENERAL	STATE OF NEW MEXICO ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT P.O. DRAWER 1508 SANTA FE NM 87504-1508		First Class Mail
STATE OF NORTH CAROLINA ATTORNEY GENERAL	STATE OF NORTH CAROLINA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 9001 MAIL SERVICE CENTER RALEIGH NC 27699-9001		First Class Mail
STATE OF NORTH DAKOTA ATTORNEY GENERAL	STATE OF NORTH DAKOTA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT STATE CAPITOL 600 E BOULEVARD AVE DEPT 125 BISMARCK ND 58505-0040	NDAG@ND.GOV	First Class Mail and Email

Exhibit A
Master Service List
Served as set forth below

DESCRIPTION	NAME	ADDRESS	EMAIL	METHOD OF SERVICE
STATE OF OHIO ATTORNEY GENERAL	STATE OF OHIO ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 30 E. BROAD ST., 14TH FLOOR COLUMBUS OH 43215		First Class Mail
STATE OF OKLAHOMA ATTORNEY GENERAL	STATE OF OKLAHOMA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 313 NE 21ST STREET OKLAHOMA CITY OK 73105		First Class Mail
STATE OF OREGON ATTORNEY GENERAL	STATE OF OREGON ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 1162 COURT STREET NE SALEM OR 97301	CONSUMER.HOTLINE@DOJ.STATE.OR.US	First Class Mail and Email
STATE OF PENNSYLVANIA ATTORNEY GENERAL	STATE OF PENNSYLVANIA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT STRAWBERRY SQUARE 16TH FLOOR HARRISBURG PA 17120		First Class Mail
STATE OF RHODE ISLAND ATTORNEY GENERAL	STATE OF RHODE ISLAND ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 150 SOUTH MAIN STREET PROVIDENCE RI 02903-0000		First Class Mail
STATE OF SOUTH CAROLINA ATTORNEY GENERAL	STATE OF SOUTH CAROLINA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT P.O. BOX 11549 COLUMBIA SC 29211-1549		First Class Mail
STATE OF SOUTH DAKOTA ATTORNEY GENERAL	STATE OF SOUTH DAKOTA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 1302 EAST HIGHWAY 14 SUITE 1 PIERRE SD 57501-8501	CONSUMERHELP@STATE.SD.US	First Class Mail and Email
STATE OF TENNESSEE ATTORNEY GENERAL	STATE OF TENNESSEE ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT P.O. BOX 20207 NASHVILLE TN 37202-0207	GINA.HANTEL@AG.TN.GOV	First Class Mail and Email
STATE OF TEXAS ATTORNEY GENERAL	STATE OF TEXAS ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT CAPITOL STATION PO BOX 12548 AUSTIN TX 78711-2548	PUBLIC.INFORMATION@OAG.STATE.TX.US	First Class Mail and Email
STATE OF UTAH ATTORNEY GENERAL	STATE OF UTAH ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT PO BOX 142320 SALT LAKE CITY UT 84114-2320	UAG@UTAH.GOV	First Class Mail and Email
STATE OF VERMONT ATTORNEY GENERAL	STATE OF VERMONT ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 109 STATE ST. MONTPELIER VT 05609-1001	AGO.BANKRUPTCIES@VERMONT.GOV AGO.INFO@VERMONT.GOV	First Class Mail and Email
STATE OF VIRGINIA ATTORNEY GENERAL	STATE OF VIRGINIA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 900 EAST MAIN STREET RICHMOND VA 23219		First Class Mail
STATE OF WASHINGTON ATTORNEY GENERAL	STATE OF WASHINGTON ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 1125 WASHINGTON ST. SE P.O. BOX 40100 OLYMPIA WA 98504-0100		First Class Mail
STATE OF WEST VIRGINIA ATTORNEY GENERAL	STATE OF WEST VIRGINIA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT STATE CAPITOL BLDG 1 ROOM E 26 CHARLESTON WV 25305	CONSUMER@WVAGO.GOV	First Class Mail and Email
STATE OF WISCONSIN ATTORNEY GENERAL	STATE OF WISCONSIN ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT WISCONSIN DEPARTMENT OF JUSTICE STATE CAPITOL, ROOM 114 EAST, P. O. BOX 7857 MADISON WI 53707-7857		First Class Mail
STATE OF WYOMING ATTORNEY GENERAL	STATE OF WYOMING ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 123 CAPITOL BUILDING 200 W. 24TH STREET CHEYENNE WY 82002		First Class Mail
TOP 30 UNSECURED CREDITORS	SYNEOS HEALTH COMMERCIAL SERVICES LLC	ATTN: WHITNEY ARMOND, III, SR. VICE PRESIDENT, DEPLOYMENT SOLUTIONS 500 ATRIUM DRIVE SOMERSET NJ 08873	WHITNEY.ARMOND@SYNEOSHEALTH.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	SYNERGISTIX INC.	ATTN: DON SCHENKER, PRESIDENT & CEO 480 SAWGRASS CORPORATE PKWY. SUITE 200 SUNRISE FL 33325	DON.SCHENKER@SYNERGISTIX.COM	First Class Mail and Email

Exhibit A
Master Service List
Served as set forth below

DESCRIPTION	NAME	ADDRESS	EMAIL	METHOD OF SERVICE
COUNSEL TO NSIGHT DRIVEN COMMUNICATIONS, LLC	TARTER KRINSKY & DROGIN LLP	ATTN: SCOTT S. MARKOWITZ 1350 BROADWAY 11TH FLOOR NEW YORK NY 10018	SMARKOWITZ@TARTERKRINSKY.COM	Email
TOP 30 UNSECURED CREDITORS	THE CEMENTWORKS LLC	ATTN: JENNIFER MATTHEWS, CEO AND PRESIDENT 32 OLD SLIP 15TH FLOOR NEW YORK NY 10005	JMATTHEWS@THEBLOC.COM RVIRAY@THECEMENTWORKS.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	THE HIBBERT COMPANY, INC.	ATTN: OKSANA POSEWA, SENIOR DIRECTOR OF SALES 400 PENNINGTON AVENUE TRENTON NJ 08618		First Class Mail
UNITED STATES TRUSTEE FOR THE SOUTHERN DISTRICT OF NEW YORK	UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK	ATTN: TARA TIAN TIAN ALEXANDER HAMILTON CUSTOM HOUSE ONE BOWLING GREEN, SUITE 515 NEW YORK NY 10004	TARA.TIANTIAN@USDOJ.GOV	First Class Mail and Email
UNITED STATES FOOD AND DRUG ADMINISTRATION	UNITED STATES FOOD AND DRUG ADMINISTRATION	ATTN: BANKRUPTCY DEPT 10903 NEW HAMPSHIRE AVENUE SILVER SPRING MD 20993		First Class Mail
UNITED STATES FOOD AND DRUG ADMINISTRATION	UNITED STATES FOOD AND DRUG ADMINISTRATION	ATTN: PRESIDENT OR GENERAL COUNSEL PO BOX 979107 ST. LOUIS MS 63197-9000		First Class Mail
UNITED STATES OF AMERICA ATTORNEY GENERAL	UNITED STATES OF AMERICA ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT US DEPT OF JUSTICE 950 PENNSYLVANIA AVE NW WASHINGTON DC 20530-0001		First Class Mail
UNITED STATES ATTORNEY’S OFFICE FOR THE SOUTHERN DISTRICT OF NEW YORK	US ATTORNEY FOR SOUTHERN DISTRICT OF NEW YORK	ATTN: BANKRUPTCY DIVISION 86 CHAMBERS STREET 3RD FLOOR NEW YORK NY 10007	JEFFREY.OESTERICHER@USDOJ.GOV LAWRENCE.FOGELMAN@USDOJ.GOV PETER.ARONOFF@USDOJ.GOV LINDA.RIFFKIN@USDOJ.GOV	First Class Mail and Email
WASHINGTON DC ATTORNEY GENERAL	WASHINGTON DC ATTORNEY GENERAL	ATTENTION BANKRUPTCY DEPT 441 4TH STREET, NW WASHINGTON DC 20001	OAG@DC.GOV	First Class Mail and Email
COUNSEL TO WILMINGTON TRUST, NATIONAL ASSOCIATION	WILMINGTON TRUST, NATIONAL ASSOCIATION	ATTN: STEVEN CIMALORE, RITA MARIE RITROVATO 1100 NORTH MARKET STREET WILMINGTON DE 19890-1605	SCIMALORE@WILMINGTONTRUST.COM RRITROVATO@WILMINGTONTRUST.COM	Email
TOP 30 UNSECURED CREDITORS	XENON PROPERTY, LLC	ATTN: GENERAL COUNSEL OR PRESIDENT ARE/283 BEAR HILL ROAD REGION NO. 46 WALTHAM MA 02451	MRIWEBFARM@CBRE.COM	First Class Mail and Email
TOP 30 UNSECURED CREDITORS	YIPKOS INC.	ATTN: MATT BOYLAN, CT 6628 SKY POINTE DRIVE SUITE 123 LAS VEGAS NV 89131	MATT@YIPKOS.COM	First Class Mail and Email

Exhibit B

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re

Chapter 11

ACORDA THERAPEUTICS, INC., *et al.*,¹

Case No. 24-22284 (DSJ)

Debtors.

Jointly Administered

Re: Docket Nos. 35 & 109

**NOTICE TO CONTRACT PARTIES TO POTENTIALLY
ASSUMED EXECUTORY CONTRACTS**

**YOU ARE RECEIVING THIS NOTICE BECAUSE YOU
OR ONE OF YOUR AFFILIATES IS A COUNTERPARTY
TO AN EXECUTORY CONTRACT WITH
THE DEBTORS AS SET FORTH ON EXHIBIT A ATTACHED HERETO.**

PLEASE TAKE NOTICE that on April 29, 2024, the United States Bankruptcy Court for the Southern District of New York (the “**Court**”) entered the *Order (A) Authorizing and Approving Bidding Procedures and Stalking Horse Bid Protections, (B) Scheduling an Auction and a Sale Hearing, (C) Approving the Form and Manner of Notice Thereof (D) Establishing Notice and Procedures for the Assumption and Assignment of Certain Executory Contracts, and (E) Granting Related Relief* [Docket No. 109] (the “**Bidding Procedures Order**”),² authorizing the Debtors to conduct an auction (the “**Auction**”) to select the party to purchase the Acquired Assets. Any Auction will be governed by the bidding procedures approved pursuant to the Bidding Procedures Order (attached to the Bidding Procedures Order as Exhibit 1, the “**Bidding Procedures**”).

PLEASE TAKE FURTHER NOTICE that, pursuant to the Bidding Procedures and the terms of any Successful Bid, the Debtors may assume and assign to the Successful Bidder the contract or agreement listed on Exhibit A (the “**Cure Notice**”) to which you are a counterparty, upon approval of the Sale. The Debtors have conducted a review of their books and records and have determined that the cure cost for unpaid monetary

¹ The Debtors in these chapter 11 cases, along with the last four (4) digits of each Debtor’s federal tax identification number, are: Acorda Therapeutics, Inc. (1168), Civitas Therapeutics, Inc. (2814), Biotie Therapies, LLC (2149), Biotie Therapies AG (N/A), Neuronex, Inc. (5094), and Acorda Therapeutics Limited (N/A). For the purposes of these chapter 11 cases, the address for the Debtors is: 2 Blue Hill Plaza, 3rd Floor, Pearl River, New York 10965.

² Capitalized terms used but not otherwise defined herein have the meanings ascribed to them in the Bidding Procedures or the Bidding Procedures Order, as applicable.

obligations under such Assigned Contracts is as set forth on **Exhibit A** attached hereto (the “Cure Costs”).

PLEASE TAKE FURTHER NOTICE that if you disagree with the proposed Cure Costs, object to a proposed assignment to the Successful Bidder of any Assigned Contract, or object to the ability of the Successful Bidder to provide adequate assurance of future performance with respect to any Assigned Contract, your objection must: (i) be in writing; (ii) comply with the applicable provisions of the Bankruptcy Code, Bankruptcy Rules, Local Bankruptcy Rules, and any order governing the administration of these Chapter 11 Cases; (iii) state with specificity the nature of the objection and, if the objection pertains to the proposed Cure Costs, state the correct cure cost alleged to be owed to the objecting counterparty to any Assigned Contract, together with any applicable and appropriate documentation in support thereof; and (iv) be filed with the Court and served and **actually received** no later than **May 20, 2024 at 4:00 p.m. (ET)** (the “**Contract Objection Deadline**”) by the Court and the following parties: (i) proposed counsel to the Debtors, Baker & McKenzie LLP (Attn: John R. Dodd (john.dodd@bakermckenzie.com), 1111 Brickell Avenue, 10th Floor, Miami, Florida 33131 and Blaire Cahn (blaire.cahn@bakermckenzie.com), 452 Fifth Avenue, New York, New York 10018); (ii) counsel to the Stalking Horse Bidder, Freshfields Bruckhaus Deringer US LP (Attn: Scott D. Talmadge (scott.talmadge@freshfields.com) and Ali Muffenbier (ali.muffenbier@freshfields.com), 3 World Trade Center, 175 Greenwich Street, New York, New York 10007); (iii) counsel for the U.S. Trustee (Attn: Tara Tiantian (Tara.Tiantian@usdoj.gov), Brian Masumoto (Brian.Masumoto@usdoj.gov), and Rachael E. Siegel (Rachael.E.Siegel@usdoj.gov), Alexander Hamilton Custom House, One Bowling Green, Suite 534, New York, New York 10004); (iv) counsel to the Ad Hoc Noteholder Group and DIP Lenders, King & Spalding LLP (Attn: Matthew Warren (mwarren@kslaw.com) and Lindsey Henrikson (lhenrikson@kslaw.com), 110 N Wacker Drive, Suite 3800, Chicago, Illinois 60606); (v) counsel to the DIP Administrative Agent, King & Spalding LLP (Attn: Geoffrey King (gking@kslaw.com), 110 N Wacker Drive, Suite 3800, Chicago, IL 60606); (vi) proposed counsel to the Creditors’ Committee, McDermott Will & Emery LLP (Attn: Darren Azman (dazman@mwe.com), Kristin K. Going (kgoing@mwe.com), and Stacy Lutkus (salutkus@mwe.com), One Vanderbilt Avenue, New York, NY 10017); and (vii) any other party that has filed a notice of appearance in these Chapter 11 Cases.

PLEASE TAKE FURTHER NOTICE that if no objection to: (i) the Cure Costs, (ii) the proposed assignment and assumption of any Assigned Contract, or (iii) adequate assurance of the Successful Bidder’s ability to perform is filed by the Contract Objection Deadline, then (a) you will be deemed to have stipulated that the Cure Cost as determined by the Debtors is correct, (b) you will be forever barred, estopped, and enjoined from asserting any additional cure cost under the proposed Assigned Contract, and (c) you will be forever barred, estopped, and enjoined from objecting to such proposed assignment to the Successful Bidder on the grounds that the Successful Bidder has not provided adequate assurance of future performance as of the closing date of the Sale.

PLEASE TAKE FURTHER NOTICE that any objection to the proposed assumption and assignment of an Assigned Contract or related Cure Costs in connection

with the Successful Bid that otherwise complies with these procedures yet remains unresolved as of the commencement of the Sale Hearing, shall be heard at a later date as may be fixed by the Court.

PLEASE THAT FURTHER NOTICE that, notwithstanding anything herein, the mere listing of any Assigned Contract on the Cure Notice does not require or guarantee that such Assigned Contract will be assumed by the Debtors at any time or assumed and assigned, and all rights of the Debtors and the Successful Bidder with respect to such executory contracts are reserved. Moreover, the Debtors explicitly reserves their rights, in their reasonable discretion, to seek to reject or assume each Assigned Contract pursuant to section 365(a) of the Bankruptcy Code and in accordance with the procedures allowing the Debtors and/or the Successful Bidder, as applicable, to designate any Assigned Contract as either rejected or assumed on a post-closing basis.

PLEASE TAKE FURTHER NOTICE that, nothing herein: (i) alters in any way the prepetition nature of the Assigned Contracts or the validity, priority, or amount of any claims of a counterparty to any Assigned Contract against the Debtors that may arise under such Assigned Contract, (ii) creates a postpetition contract or agreement, or (iii) elevates to administrative expense priority any claims of a counterparty to any Assigned Contract against the Debtors that may arise under such Assigned Contract.

PLEASE TAKE FURTHER NOTICE that you may obtain additional information concerning the above-captioned Chapter 11 Cases at the website maintained in these Chapter 11 Cases at <https://cases.ra.kroll.com/Acorda>.

PLEASE TAKE FURTHER NOTICE that questions regarding any proposed assumption and assignment of an Assigned Contract or related Cure Costs in connection with the Successful Bid may be directed to proposed counsel to the Debtors, Baker & McKenzie LLP via e-mail at john.dodd@bakermckenzie.com and blaire.cahn@bakermckenzie.com, and proposed counsel to the Creditors' Committee, McDermott Will & Emery LLP, via e-mail at dazman@mwe.com, kgoing@mwe.com, and salutkus@mwe.com.

[Remainder of page intentionally left blank]

Dated: May 1, 2024

/s/ John R. Dodd

John R. Dodd (admitted *pro hac vice*)
BAKER & McKENZIE LLP
1111 Brickell Avenue, 10th Floor
Miami, FL 33131
Telephone: 305-789-8900
Facsimile: 305-789-8953
Email: john.dodd@bakermckenzie.com

and

Blaire Cahn
BAKER & McKENZIE LLP
452 Fifth Avenue
New York, NY 10018
Telephone: 212-626-4100
Facsimile: 212-310-1600
Email: blaire.cahn@bakermckenzie.com

*Proposed Counsel for the Debtors
and Debtors-in-Possession*

Exhibit A

Cure Notice

No.	Contract	Counter Party(s)	Cure Amount (\$)
1.	Pre-Launch Agreement, dated as of December 15, 2021, by and between Acorda Therapeutics, Inc. and RIS RX.	RIS RX	-
2.	First Amendment to the Master Patient Support Hub Services Agreement, dated as of September 1, 2022, by and between Acorda Therapeutics, Inc. and RIS RX.	RIS RX	-
3.	Master Patient Support Hub Services Agreement, dated as of February 15, 2022, by and between Acorda Therapeutics, Inc. and RIS RX	RIS RX	\$54,780.50
4.	First Amendment to Adverse Event and Product Complaint Reporting Agreement, dated as of August 30, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	-
5.	First Amendment to the Master Direct Product Purchase and Dispensing Agreement, dated as of September 1, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	-
6.	Adverse Event and Product Complaint Reporting Agreement, dated as of February 15, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	-
7.	Master Direct Product Purchase and Dispensing Agreement, dated as of February 15, 2022, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX	\$25,285.11

No.	Contract	Counter Party(s)	Cure Amount (\$)
8.	Second Amendment to the Master Patient Support Hub Services Agreement, dated as of November 18, 2022, by and between RIS Rx and Acorda Therapeutics, Inc.	RIS RX	-
9.	Third Amendment to the Master Patient Support Hub Services Agreement, dated as of March 8, 2023, by and between RIS Rx and Acorda Therapeutics, Inc.	RIS RX	-
10.	Fourth Amendment to the Master Direct Product Purchase and Dispensing Agreement, dated as of February 15, 2022, by and between SterlingRx, Inc. and Acorda Therapeutics, Inc.	SterlingRX	-
11.	Fourth Amendment to the Pharmacy Services Agreement, dated as of February 15, 2022, by and between SterlingRx, Inc. and Acorda Therapeutics, Inc.	SterlingRX	-
12.	Project Addendum #1 to the Master Market Access Service Agreement, dated as of July 19, 2018, by and between Acorda Therapeutics, Inc. and Covance Specialty Pharmacy LLC	Covance Specialty Pharmacy LLC	-
13.	McKesson Corporation Core Distribution Agreement, dated as of October 8, 2007, by and between Acorda Therapeutics, Inc. and the McKesson Corporation	McKesson Corporation	-
14.	Master Consulting Agreement, dated October 19, 2021, by and between Acorda Therapeutics Inc. and Dennis Brodsky	Dennis Brodsky	-
15.	Master Consulting Agreement, dated December 31, 2023, by and between Acorda	Alex Bonacum	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and Alex Bonacum		
16.	Master Consulting Agreement, dated. April 24, 2017, by and between Acorda Therapeutics Inc. and Pharmacovigilance Physician Services LLC	Pharmacovigilance Physician Services LLC	-
17.	Master Consulting Agreement, dated as of November 13, 2020, by and between Acorda Therapeutics, Inc. and Opus Regulatory, Inc.	Opus Regulatory, Inc.	-
18.	Master Consulting Agreement, dated January 10, 2023, by and between Acorda Therapeutics, Inc. and Alex Bonacum	Alex Bonacum	-
19.	Master Consulting Agreement, dated as of February 15, 2024, by and between Acorda Therapeutics, Inc. and Gilani, LLC	Gilani LLC	\$6,000.00
20.	Schedule #1 under the Master Consulting Agreement, dated as of March 1, 2024, by and between Acorda Therapeutics, Inc. and Scientific Research Partners, LLC	Scientific Research Partners, LLC	-
21.	Master Consulting Agreement, dated as of January 8, 2024, by and between Acorda Therapeutics, Inc. and Manfred Fischer Consulting	Scientific Research Partners, LLC	-
22.	Master Consulting Agreement, dated as of March 1, 2024, by and between Acorda Therapeutics, Inc. and Scientific Research Partners, LLC	Scientific Research Partners, LLC	-
23.	Master Consulting Agreement, dated as of January 1, 2024, by and between Acorda Therapeutics, Inc. and SA Global Solutions, LLC.	SA Global Solutions, LLC	-
24.	Bill of Materials Form, dated as of January 30, 2023, by and	Sharp Corporation	\$8,825.00

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Sharp Corporation and Acorda Therapeutics, Inc.		
25.	Bill of Materials Form, dated as of March 3, 2022, by and between Sharp Corporation and Acorda Therapeutics, Inc.	Sharp Corporation	-
26.	Bill of Materials Form, dated as of August 14, 2023, by and between Sharp Corporation and Acorda Therapeutics, Inc.	Sharp Corporation	-
27.	Documents MBR-0839, MBR-0840, MBR-0982, MBR-1316, MBR-1317 dated as of January 4, 2024, by and between Catalent Pharma Solutions and Acorda Therapeutics, Inc.	Catalent Pharma Solutions	-
28.	Documents MBR-0839, MBR-0840, MBR-0982, MBR-1303, MBR-1304 dated as of January 4, 2024, by and between Catalent Pharma Solutions and Acorda Therapeutics, Inc.	Catalent Pharma Solutions	-
29.	Bill of Materials Form, dated as of August 31, 2023, by and between Sharp Corporation and Acorda Therapeutics, Inc.	Sharp Corporation	-
30.	Packaging Work Order – Bill of Materials, dated as of April 13, 2023, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
31.	Processing Master – Cover Page and Related Documents, dated as of September 29, 2023, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
32.	Main Agreement, dated December 16, 2014, by and between Acorda Therapeutics, Inc. and NDA Group AB	NDA Group AB	\$18,975.00
33.	Supply Agreement dated as of June 30, 2009 between Acorda Therapeutics, Inc and Biogen IDEC International GMBH	Biogen IDEC International GMBH	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
34.	Collaboration and License Agreement dated as of June 30, 2009, by and between Acorda Therapeutics, Inc. and Biogen IDEC International GmbH	Biogen IDEC International GMBH	-
35.	Addendum #1 to the Collaboration and License Agreement and Supply Agreement, dated as of May 21, 2010, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
36.	Addendum #2 to the Collaboration and License Agreement, dated as of March 29, 2012, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
37.	Addendum #3 to Collaboration and License Agreement and to Supply Agreement, dated as of February 14, 2013, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
38.	Addendum #4 to the Collaboration and License Agreement, dated as of October 28, 2012, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
39.	Amended and Restated Addendum #2 to the Supply Agreement, dated as of June 6, 2016, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
40.	Amendment #1 to Addendum #1 to the Collaboration and License Agreement and Supply Agreement, dated as of May 16, 2011, by and between	Biogen IDEC International GMBH	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Acorda Therapeutics, Inc. and Biogen Idec International GmbH		
41.	Amendment #1 to Manufacturing Services Agreement, dated as of August 29, 2011, by and between Acorda Therapeutics, Inc. and Patheon Inc.	Patheon Inc.	-
42.	Quality Agreement, dated as of July 20, 2021, by and between Biogen International GmbH and Alkermes Pharma Ireland Limited	Biogen International GmbH	-
43.	Addendum #2 to the Supply Agreement, dated as of August 28, 2010, by and between Acorda Therapeutics, Inc. and Biogen Idec International GmbH	Biogen IDEC International GMBH	-
44.	Fampridine Safety Data Exchange Agreement, dated as of May 24, 2023, by and between Acorda Therapeutics, Inc. and Biogen International GmbH	Biogen International GMBH	-
45.	Manufacturing Services Agreement, dated as of December 31, 2022, by and between Acorda Therapeutics, Inc. and Catalent Massachusetts LLC	Catalent Massachusetts LLC	\$1,872,711.06
46.	Asset Purchase and License Agreement, dated as of December 27, 2010, by and between Corregidor Therapeutics, Inc. and Alkermes, Inc.	Alkermes, Inc.	\$284,509.55
47.	First Amendment to Manufacturing Services Agreement, dated as of March 6, 2023, by and between Acorda Therapeutics, Inc. and Catalent Massachusetts LLC	Catalent Massachusetts LLC	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
48.	Quality Agreement, dated as of May 6, 2021, by and between Acorda Therapeutics, Inc. and Catalent Massachusetts LLC	Catalent Massachusetts LLC	-
49.	Amendment to Asset Purchase and License Agreement, dated as of December 9, 2011, by and between Civitas Therapeutics, Inc. and Alkermes, Inc.	Alkermes, Inc.	-
50.	Second Amendment to Asset Purchase and License Agreement, dated as of December 19, 2014, by and between Civitas Therapeutics, Inc. and Alkermes, Inc.	Alkermes, Inc.	-
51.	Feasibility Study Agreement, dated December 26, 2014, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
52.	Amendment #1 to the Feasibility Study Agreement, dated March 12, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
53.	Amendment #1 to Statement of Work #1, dated March 12, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
54.	Amendment #2 to Statement of Work #1, dated September 16, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
55.	Amendment #3 to Statement of Work #1, dated October 5, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
56.	Master Development and Clinical Supply Agreement, dated September 15, 2015, by and between Acorda	Metrics, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and Metrics, Inc.		
57.	Patent License Agreement, dated November 1, 2016, by and between Acorda Therapeutics, Inc. and Mayne Pharma, Inc. (d/b/a Metrics Contract Services)	Mayne Pharma, Inc.	-
58.	Quote for Analytical Development, CTM Manufacture, Release Testing and Stability for Dalfampridine (4-aminopyridine) MR Tablets, 22mg, dated as of September 24, 2015, from Metrics Contract Services to Acorda Therapeutics, Inc.	Metrics, Inc.	-
59.	Statement of Work #1, dated January 5, 2015, by and between Acorda Therapeutics, Inc. and Metrics, Inc.	Metrics, Inc.	-
60.	Medicare Part D Rebate Agreement, dated as of January 1, 2021, by and between Acorda Therapeutics, Inc. and CVS Caremark Part D Services, L.L.C.	CVS Caremark Part D Services, L.L.C.	-
61.	Rebate Agreement, dated as of July 1, 2015, by and between Acorda Therapeutics, Inc. and CaremarkPCS Health, L.L.C.	CaremarkPCS Health, L.L.C.	-
62.	Medicare Part D Rebate Agreement, dated as of April 1, 2021, by and between Acorda Therapeutics, Inc. and Elixir Rx Solutions of Nevada, LLC	Elixir Rx Solutions of Nevada, LLC	-
63.	Rebate Program Agreement, dated as of July 1, 2019, by and between Acorda Therapeutics, Inc. and Ascent Health Services LLC	Ascent Health Services LLC	\$133,642.11
64.	Preferred Savings Grid Rebate Program Agreement, dated as of July 1, 2019, by and	Express Scripts, Inc.	\$58,258.70

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and Express Scripts, Inc.		
65.	Medicare Part D Rebate Agreement, dated as of January 1, 2019, by and between Acorda Therapeutics, Inc. and Express Scripts Senior Care Holdings, Inc.	Express Scripts Senior Care Holdings, Inc.	-
66.	Kaiser Permanente Product Rebate and Discount Agreement, dated as of September 1, 2020, by and between Acorda Therapeutics, Inc., Kaiser Foundations Hospitals and Kaiser Foundation Health Plan, Inc.	Kaiser Foundations Hospitals Kaiser Foundation Health Plan, Inc.	\$17,048.51
67.	Rebate and Administrative Fee Agreement, dated as of January 1, 2021, by and between Acorda Therapeutics, Inc. and Navitus Health Solutions, LLC	Navitus Health Solutions, LLC	-
68.	Medicare Part D Rebate Agreement, dated as of January 1, 2016, by and between Acorda Therapeutics, Inc. and OptumRx, Inc.	OptumRx, Inc.	-
69.	Rebate Agreement, dated as of January 1, 2013, by and between Acorda Therapeutics, Inc. and OptumRx, Inc.	OptumRx, Inc.	-
70.	Commercial Rebate Agreement, dated as of January 1, 2021, by and between Acorda Therapeutics, Inc. and Zinc Health Services, LLC	Zinc Health Services, LLC	\$342,440.03
71.	Second Amendment to Supply Agreement, dated as of February 4, 2010, by and between AmerisourceBergen Drug Corporation and Acorda Therapeutics, Inc.	AmerisourceBergen Drug Corporation	-
72.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and among Acorda	AmerisourceBergen Drug Corporation	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc., ASD Specialty Healthcare, Inc. and AmerisourceBergen Specialty Group, Inc.		
73.	Seventh Amendment to Distribution Services Agreement, dated as of February 1, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, LLC	ASD Specialty Healthcare, LLC	-
74.	Supply Agreement, dated as of September 20, 2004, by and between Acorda Therapeutics, Inc. and AmerisourceBergen Drug Corporation	AmerisourceBergen Drug Corporation	-
75.	Amendment to Supply Agreement, dated as of May 1, 2008, by and between AmerisourceBergen Drug Corporation and Acorda Therapeutics, Inc.	AmerisourceBergen Drug Corporation	-
76.	Ninth Amendment to Distribution Services Agreement, dated as of September 6, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, LLC.	ASD Specialty Healthcare, LLC	-
77.	Distribution Services Agreement, dated as of February 1, 2011, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, LLC.	\$19,888.80
78.	Quality Agreement, dated as of April 4, 2019, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	-
79.	U.S. Principal Party in Interest (USPPI) Affidavit and Power of Attorney, dated as of August 22, 2017, by and among Acorda Therapeutics, Inc.,	Cardinal Health 105 Inc. Cardinal Health 110, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Cardinal Health 105 Inc. and Cardinal Health 110, Inc.		
80.	Letter re amendment to Operating Guidelines, dated as of March 3, 2020, by and between Cardinal Health Specialty Solutions and Acorda Therapeutics, Inc.	Cardinal Health Specialty Solutions	-
81.	Third Amendment to Distribution Agreement, dated as of September 28, 2012 by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	-
82.	Distribution Agreement, dated as of August 19, 2004, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc. f.k.a. Cardinal Health PTS, LLC	Cardinal Health 105, Inc. f.k.a. Cardinal Health PTS, LLC	-
83.	U.S. Principal Party in Interest (USPPI) Affidavit, dated as of January 8, 2019, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	-
84.	U.S. Principal Party in Interest (USPPI) Affidavit, dated as of December 2, 2020, by and between Acorda Therapeutics, Inc. and Cardinal Health 105, Inc.	Cardinal Health 105, Inc.	-
85.	First Amendment to Distribution Agreement, dated as of July 26, 2005, by and between Cardinal Health PTS, LLC and Acorda Therapeutics, Inc.	Cardinal Health PTS, LLC	-
86.	Second Amendment to Distribution Agreement, dated as of January 22, 2010, by and between Cardinal Health 105, Inc. and Acorda Therapeutics, Inc.	Cardinal Health 105, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
87.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and among Acorda Therapeutics, Inc., Express Scripts, Inc. and Accredo Health Group, Inc.	Express Scripts, Inc. Accredo Health Group, Inc.	-
88.	Product Purchase and Dispensing Agreement, dated as of April 15, 2016, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
89.	4 th Amendment to Pharmacy Services Agreement, dated as of April 22, 2021, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
90.	Second Amendment to Specialty Pharmacy Services Agreement, dated as of July 1, 2018, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
91.	First Amendment to Specialty Pharmacy Services Agreement, dated as of April 20, 2018, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
92.	Third Amendment to Specialty Pharmacy Data Services Agreement, dated as of June 25, 2015, by and between Acorda Therapeutics, Inc. and Accredo Health Group Inc.	Accredo Health Group, Inc.	-
93.	Third Amendment to Specialty Pharmacy Purchase and Dispensing Agreement, dated as of June 25, 2015, by and between Acorda Therapeutics, Inc. and Accredo Health Group Inc.	Accredo Health Group, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
94.	Pharmacy Services Agreement dated as of April 15, 2016, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	\$57,515.00
95.	Specialty Pharmacy Data Services Agreement dated as of February 26, 2010, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
96.	Specialty Pharmacy Purchase and Dispensing Agreement, dated as of February 26, 2010, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
97.	Third Amendment to Specialty Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
98.	Second Amendment to Specialty Pharmacy Services Agreement, dated as of July 1, 2018, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
99.	Draft Sixth Amendment to Specialty Pharmacy Purchase and Dispensing Agreement, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	\$33,714.73
100.	Third Amendment to Pharmacy Services Agreement, dated as of December 31, 2020, by and between Acorda Therapeutics, Inc. and Caremark, LLC.	Caremark, L.L.C.	-
101.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and between Acorda	Caremark, L.L.C.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and Caremark, LLC.		
102.	Pharmacy Services Agreement, dated as of January 1, 2019, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
103.	Product Purchase and Dispensing Agreement, dated as of October 1, 2017, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
104.	Product Purchase and Dispensing Agreement, dated as of January 1, 2019, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
105.	Fourth Amendment to Pharmacy Services Agreement, dated as of May 1, 2021, by and between Acorda Therapeutics, Inc. And Caremark, L.L.C.	Caremark, L.L.C.	-
106.	First Amendment to Pharmacy Services Agreement, dated as of March 26, 2018, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
107.	Second Amendment to Pharmacy Services Agreement, dated as of May 1, 2020, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
108.	Pharmacy Services Agreement, dated as of October 1, 2017 , by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
109.	First Amendment to Pharmacy Services Agreement, dated as of March 26, 2018, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
110.	Third Amendment to Pharmacy Services Agreement, dated as of December 31, 2020, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
111.	Fourth Amendment to Pharmacy Services Agreement, dated as of May 1, 2021, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
112.	Fifth Amendment to Pharmacy Services Agreement, dated as of March 1, 2022, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
113.	Sixth Amendment to Pharmacy Services Agreement, dated as of May 9, 2022, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
114.	Second Amendment to Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
115.	Third Amendment to Specialty Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda Therapeutics, Inc. and Accredo Health Group, Inc.	Accredo Health Group, Inc.	-
116.	Second Amendment to Pharmacy Services Agreement, dated as of May 1, 2020, by and between Acorda Therapeutics, Inc. and Caremark, L.L.C.	Caremark, L.L.C.	-
117.	Third Amendment to Specialty Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
118.	Change Order #7 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of February 10, 2020, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
119.	Change Order #8 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 11, 2020, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
120.	Change Order #9 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 11, 2020, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
121.	Change Order #10 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 27, 2020, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
122.	Project Addendum #4 to the Master Market Access Services Agreement, dated as of June 22, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
123.	Master Specialty Pharmacy Services Agreement, dated as of July 19, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
124.	Project Addendum #2 to the Master Market Access Services Agreement, dated as of May 1, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
125.	Master Market Access Services Agreement, dated as of August 6, 2015, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
126.	Project Addendum #1 to the Master Market Access Services Agreement, dated as of September 2, 2015, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
127.	Project Addendum #3 to the Master Market Access Services Agreement, dated as of August 8, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
128.	Third Amendment to Pharmacy Services Agreement, dated as of February 15, 2023, by and between Acorda Therapeutics, Inc. and SterlingRX, Inc.	SterlingRX, Inc.	-
129.	Third Amendment to the Master Patient Support Hub Services Agreement, dated as of March 8, 2023, by and between Acorda Therapeutics, Inc. and RIS Rx.	RIS Rx	-
130.	Second Amendment to Master Direct Product Purchase and Dispensing Agreement, dated as of February 15, 2023, by and between Acorda Therapeutics, Inc. and SterlingRx, Inc.	SterlingRX, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
131.	Inventory Amendment to Pharmacy Services Agreement, dated as of April 1, 2021, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
132.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
133.	Pharmacy Services Agreement, dated as of April 1, 2016, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
134.	Product Purchase and Dispensing Agreement, dated as of April 1, 2016, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
135.	Inbrija Product Attachment to Product Purchase and Dispensing Agreement, dated as of February 22, 2019, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
136.	First Amendment to Pharmacy Services Agreement, dated as of December 1, 2017, by and between Acord Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
137.	Second Amendment to Pharmacy Services Agreement, dated as of April 1, 2016, by and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.	Humana Pharmacy, Inc.	-
138.	Inbrija Product Attachment to Pharmacy Services Agreement, dated as of March 21, 2019, by	Humana Pharmacy, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	and between Acorda Therapeutics, Inc. and Humana Pharmacy, Inc.		
139.	Fourth Amendment to Specialty Pharmacy Services Agreement, dated as of May 1, 2021, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	-
140.	Product Purchase and Dispensing Agreement, dated as of April 1, 2016, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine Inc.	BriovaRx of Maine, Inc.	-
141.	Pharmacy Services Agreement, dated as of April 1, 2016, by and between Acorda, by and Therapeutics, Inc. and BriovaRx of Maine Inc.	BriovaRx of Maine, Inc.	\$68,380.00
142.	Specialty Pharmacy Data Services Agreement, dated as of January 8, 2015, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine Inc.	BriovaRx of Maine, Inc.	-
143.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc. and Optum Rx, Inc.	BriovaRx of Maine, Inc.	-
144.	First Amendment to Inbrija Product Attachment to Pharmacy Services Agreement, dated as of November 1, 2019, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	-
145.	Third Amendment to Specialty Pharmacy Services Agreement, dated as of April 1, 2020, by and between Acorda	BriovaRx of Maine, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and BriovaRx of Maine, Inc.		
146.	First Amendment to Specialty Pharmacy Services Agreement, dated as of March 1, 2018, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	-
147.	Second Amendment to Specialty Pharmacy Services Agreement, dated as of March 1, 2018, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	-
148.	Inbrija Product Attachment to Product Purchase and Dispensing Agreement, dated as of January 3, 2019, by and between Acorda Therapeutics, Inc. and BriovaRx of Maine, Inc.	BriovaRx of Maine, Inc.	-
149.	Product Purchase and Dispensing Agreement, dated as of August 31, 2020, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	-
150.	Pharmacy Services Agreement, dated as of August 31, 2020, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	\$80,951.54
151.	Pharmacy Services Agreement, dated as of April 1, 2021, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	-
152.	Pharmacy Services Agreement, dated as of September 1, 2017, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	\$41,540.00
153.	Product Purchase and Dispensing Agreement, dated as of September 1, 2017, by and between Acorda	Walgreen Co.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and Walgreen Co.		
154.	Letter re Inbrija Return Goods Policy Notice Amendment, dated as of November 22, 2019, by and among Acorda Therapeutics, Inc. and Walgreens Co. and Walgreens Specialty Pharmacy, L.L.C.	Walgreens Co. Walgreens Specialty Pharmacy, L.L.C.	-
155.	Amendment No. 1 to Ampyra Pharmacy Services Agreement, dated as of April 28, 2020, by and between Acorda Therapeutics, Inc. and Walgreen Co.	Walgreen Co.	-
156.	First Amendment to Distribution Services Agreement, dated as of July 13, 2011, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
157.	Second Amendment to Distribution Services Agreement, dated as of November 14, 2012, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
158.	Third Amendment to Distribution Services Agreement, dated as of July 1, 2014, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
159.	Fourth Amendment to Distribution Services Agreement, dated as of November 4, 2014, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
160.	Fifth Amendment to Distribution Services Agreement, dated as of December 22, 2014, by and	ASD Specialty Healthcare, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.		
161.	Sixth Amendment to Distribution Services Agreement, dated as of October 21, 2015, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
162.	Seventh Amendment to Distribution Services Agreement, dated as of February 1, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
163.	Eighth Amendment to Distribution Services Agreement, dated as of June 25, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
164.	Ninth Amendment to Distribution Services Agreement, dated as of September 6, 2019, by and between Acorda Therapeutics, Inc. and ASD Specialty Healthcare, Inc.	ASD Specialty Healthcare, Inc.	-
165.	Amendment No. 1 to Master Specialty Pharmacy Services Agreement, dated as of August 1, 2020, by and between Acorda Therapeutics, Inc. and Covance Specialty Pharmacy LLC.	Covance Specialty Pharmacy LLC.	-
166.	Change Order #1 to Project Addendum #1 to the Master Specialty Pharmacy Services Agreement, dated as of January 1, 2022, by and between Labcorp Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Labcorp Specialty Pharmacy LLC	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
167.	Change Order #2 to Project Addendum #1 to the Master Specialty Pharmacy Services Agreement, dated as of January 20, 2022, by and between Labcorp Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Labcorp Specialty Pharmacy LLC	-
168.	Project Addendum #1 to the Master Market Access Services Agreement, dated as of July 19, 2018, by and between Acorda Therapeutics, Inc. and Covance Specialty Pharmacy LLC.	Covance Specialty Pharmacy LLC	-
169.	Project Addendum #2 to the Master Market Access Services Agreement, dated as of May 1, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
170.	Change Order #2 to Project Addendum #2 to the Master Market Access Services Agreement, dated as of October 30, 2018, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
171.	Change Order #2 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of April 15, 2019, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
172.	Change Order #2 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of April 15, 2019, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
173.	Change Order #3 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 22, 2019, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
174.	Change Order #4 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of June 15, 2019, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
175.	Change Order #7 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of February 10, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
176.	Change Order #8 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 11, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
177.	Change Order #9 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 11, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
178.	Change Order #1 to Project Addendum #2 and #3 to the Master Market Access Services Agreement, dated as of September 18, 2018, by and	Covance Market Access Services Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.		
179.	Change Order #12 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of April 1, 2021, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
180.	Change Order #10 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of May 27, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
181.	Change Order #11 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of July 17, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
182.	Change Order #6 to Project Addendum #3 to the Master Market Access Services Agreement, dated as of February 24, 2020, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
183.	Change Order #1 to Project Addendum #1 to the Master Market Access Services Agreement, dated as of May 20, 2016, by and between Acorda Therapeutics, Inc. and Covance Market Access Services Inc.	Covance Market Access Services Inc.	-
184.	Confidential Disclosure Agreement, dated as of May 26, 2017, by and between Covance Market Access	Covance Market Access Services Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Services Inc. and Acorda Therapeutics, Inc.		
185.	Project Addendum #4 to the Master Market Access Services Agreement, dated as of June 22, 2018, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	\$310,036.54
186.	Master Market Access Services Agreement, dated as of August 6, 2015, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
187.	Project Addendum #5 to Master Market Access Services Agreement, dated as of January 1, 2022, by and between Labcorp Peri-Approval and Commercialization Inc. and Acorda Therapeutics, Inc.	Labcorp Peri-Approval and Commercialization Inc.	-
188.	Project Addendum #1 to Master Market Access Services Agreement, dated as of September 2, 2015, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
189.	Project Addendum #3, dated as of August 8, 2018, by and between Covance Market Access Services Inc. and Acorda Therapeutics, Inc.	Covance Market Access Services Inc.	-
190.	Change Order #2 to Project Addendum #1, dated as of January 1, 2024, by and between Fortrea Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Fortrea Specialty Pharmacy LLC	\$22,914.22
191.	Second Amendment to Master Specialty Pharmacy Services Agreement, dated as of May 1, 2023, by and between Fortrea	Fortrea Specialty Pharmacy LLC	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Specialty Pharmacy LLC and Acorda Therapeutics, Inc.		
192.	Amendment #1 to Master Specialty Pharmacy Services Agreement, dated as of August 1, 2020, by and between Covance Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Covance Specialty Pharmacy LLC	-
193.	Change Order #1 to Project Addendum #1, dated as of January 1, 2022, by and between Labcorp Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Labcorp Specialty Pharmacy LLC	-
194.	Master Specialty Pharmacy Services Agreement, dated as of July 19, 2018, by and between Acorda Therapeutics, Inc. and Fortrea Specialty Pharmacy LLC (f/k/a Covance Specialty Pharmacy LLC)	Fortrea Specialty Pharmacy LLC	-
195.	Project Addendum #1, dated as of July 19, 2018, by and between Covance Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Covance Specialty Pharmacy LLC	-
196.	Change Order #2 to Project Addendum #1, dated as of January 20, 2022, by and between Labcorp Specialty Pharmacy LLC and Acorda Therapeutics, Inc.	Labcorp Specialty Pharmacy LLC	-
197.	Specialty Pharmacy Purchase and Dispensing Agreement, dated as of September 28, 2023, by and between Acorda Therapeutics, Inc. and Gentry Health Services Inc.	Gentry Health Services Inc.	\$19,670.00
198.	Specialty Pharmacy Services Agreement, dated as of September 28, 2023, by and between Acorda Therapeutics, Inc. and Gentry Health Services Inc.	Gentry Health Services Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
199.	Trading Partner Account Set-up Form, dated as of September 19, 2019, by and between University of Wisconsin Hospitals and Clinics and Acorda Therapeutics, Inc.	University of Wisconsin Hospitals and Clinics	-
200.	Inflation Agreement, dated as of July 1, 2019, by and between Acorda Therapeutics, Inc. and Ascent Health Services LLC	Ascent Health Services LLC	-
201.	Inflation Agreement, dated as of July 1, 2019, by and between Acorda Therapeutics, Inc. and Express Scripts, Inc.	Express Scripts, Inc.	-
202.	Medicare Part D Rebate Inflation Agreement, dated as of July 1, 2020, by and between Acorda Therapeutics, Inc. and Express Scripts Senior Care Holdings, Inc.	Express Scripts Senior Care Holdings, Inc.	-
203.	Amendment to Distribution Agreement for Spain, dated as of November 8, 2021, by and between Esteve Pharmaceuticals, S.A. and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals, S.A.	-
204.	Distribution Agreement, dated as of July 20, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals, S.A.	Esteve Pharmaceuticals, S.A.	-
205.	Supply Agreement, dated as of May 3, 2023, by and between Acorda Therapeutics, Inc. and Hangzhou Chance Pharmaceuticals Co., Ltd.	Hangzhou Chance Pharmaceuticals Co., Ltd.	-
206.	Exclusive Distribution Agreement, dated as of May 3, 2023, by and between Acorda Therapeutics, Inc. and Hangzhou Chance Pharmaceuticals Co., Ltd.	Hangzhou Chance Pharmaceuticals Co., Ltd.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
207.	Distribution Agreement, dated as of November 8, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals GmbH	Esteve Pharmaceuticals GmbH	-
208.	Supply Agreement, dated as of November 8, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals GmbH	Esteve Pharmaceuticals GmbH	-
209.	Distribution Agreement, dated as of May 11, 2022, by and between Acorda Therapeutics, Inc. and Pharma Consulting Group, S.A.	Pharma Consulting Group, S.A.	-
210.	Supply Agreement, dated as of May 11, 2022, by and between Acorda Therapeutics, Inc. and Pharma Consulting Group, S.A.	Pharma Consulting Group, S.A.	-
211.	Supply Agreement, dated as of July 20, 2021, by and between Acorda Therapeutics, Inc. and Esteve Pharmaceuticals, S.A.	Esteve Pharmaceuticals, S.A.	-
212.	Amendment to Distribution Agreement for Germany, dated as of May 23, 2023, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals, GmbH	-
213.	Amendment to Supply Agreement for Germany, dated as of May 23, 2023, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals, GmbH	-
214.	First Amendment to the Supply Agreement, dated as of May 10, 2022, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals, GmbH	-
215.	Quality Agreement, dated as of September 19, 2022, by and between Acorda Therapeutics Ireland Limited and Adoh B.V.	Adoh B.V.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
216.	General Service Agreement dated as of October 16, 2018 between Acorda Therapeutics, Inc., Acorda Therapeutics Ireland Limited and Adoh B.V.	Adoh B.V.	\$14,524.17
217.	Importer Agreement, dated as of August 4, 2021, by and between Acorda Therapeutics, Inc. and MedEnvoy Global B.V.	MedEnvoy Global B.V.	-
218.	Safety Data Exchange Agreement, dated as of November 30, 2023, by and among Acorda Therapeutics, Inc., Esteve Pharmaceuticals GMBH and Esteve Pharmaceuticals S.A.	Esteve Pharmaceuticals GMBH Esteve Pharmaceuticals S.A.	-
219.	Third Amendment to the Distribution Agreement for Germany, dated as of December 14, 2023, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals GMBH	-
220.	Second Amendment to the Distribution Agreement for Germany, dated as of December 14, 2023, by and between Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals GmbH	-
221.	First Amendment to the Medicare Part D Program Rebate Agreement, dated as of January 1, 2022, by and between CVS Caremark Part D Services, LLC and Acorda Therapeutics, Inc.	CVS Caremark Part D Services, LLC	\$141,601.71
222.	Medicare Part D Rebate Agreement, dated as of January 1, 2016, by and between Acorda Therapeutics, Inc. and OptumRx, Inc.	OptumRx, Inc.	-
223.	Rebate Agreement, dated as of January 1, 2013, by and	OptumRx, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and OptumRx, Inc.		
224.	Sixth Amendment to the Medicare Part D Rebate Agreement, dated as of January 1, 2023, by and between OptumRx, Inc. and Acorda Therapeutics, Inc.	OptumRx, Inc.	\$109,300.76
225.	First Amendment to the Master Services Agreement, dated as of March 9, 2023, by and between Riparian LLC and Acorda Therapeutics, Inc.	Riparian LLC	-
226.	Master Services Agreement, dated as of January 16, 2019, by and between Acorda Therapeutics, Inc. and TrialCard Incorporated	TrialCard Incorporated	-
227.	Master Services Agreement, dated as of April 15, 2020, by and between Acorda Therapeutics, Inc. and Riparian, LLC	Riparian LLC	-
228.	Statement of Work #3, dated as of September 28, 2023, by and between Riparian LLC and Acorda Therapeutics, Inc.	Riparian LLC	-
229.	TrialCard Statement of Work: 2023 Engage HCP PTR Program (Inside Sales Program), dated as of January 1, 2023, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
230.	First Amendment to the Master Services Agreement, dated as of July 15, 2022, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
231.	TrialCard Statement of Work Inbrija Copay Program Change Order Number 6, dated as of January 1, 2023, by and between TrialCard	TrialCard Incorporated	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Incorporated and Acorda Therapeutics, Inc.		
232.	Third Amendment to the Master Services Agreement, dated as of November 15, 2023, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
233.	TrialCard Statement of Work Change Order Number 1: Inbrija Co-pay Program, dated as of September 5, 2019, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
234.	TrialCard Statement of Work Change Order Number 2: Inbrija Co-pay Program, dated as of February 1, 2020, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
235.	TrialCard Statement of Work: Co-pay Services: Inbrija Co-pay Program, dated as of January 16, 2019, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
236.	Statement of Work: 2024 Inbrija Copay Program, dated as of January 1, 2024, by and between Mercalis Inc. and Acorda Therapeutics, Inc.	Mercalis Inc.	-
237.	TrialCard Statement of Work Change Order Number 3: Inbrija Co-pay Program, dated as of May 8, 2020, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
238.	Second Amendment to the Master Services Agreement, dated as of January 11, 2023, by and between TrialCard	TrialCard Incorporated	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Incorporated and Acorda Therapeutics, Inc.		
239.	TrialCard Statement of Work Inbrija Copay Program: Change Order Number 7, dated as of March 24, 2022, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
240.	Statement of Work: Acorda Therapeutics, Inc. 2024 Inside Sales Program, dated as of January 1, 2024, by and between Mercalis Inc. and Acorda Therapeutics, Inc.	Mercalis Inc.	-
241.	TrialCard Statement of Work: Ampyra Copay Assistance Program, dated as of August 1, 2022, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
242.	TrialCard Statement of Work Change Order Number 4: Inbrija Co-pay Program, dated as of March 1, 2021, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
243.	TrialCard Statement of Work Change Order Number 5: Inbrija Co-pay Program, dated as of April 2, 2021, by and between TrialCard Incorporated and Acorda Therapeutics, Inc.	TrialCard Incorporated	-
244.	Confidential Disclosure Agreement, dated as of May 28, 2009, by and among Regis Technologies, Inc., Bayer HealthCare Pharmaceuticals Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc., Bayer HealthCare Pharmaceuticals Inc.	-
245.	Amendment #1 to Master Services Agreement, dated as of March 5, 2010, by and	Regis Technologies, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Regis Technologies, Inc. and Acorda Therapeutics, Inc.		
246.	Amendment #2 to Master Services Agreement, dated as of March 4, 2012, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	-
247.	Amendment #3 to Master Services Agreement, dated as of March 3, 2013, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	-
248.	Confidential Disclosure Agreement, dated as of February 7, 2008, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	-
249.	Confidential Disclosure Agreement, dated as of June 3, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies, Inc.	-
250.	Consent Letter, dated as of May 18, 2009, by and among Regis Technologies, Inc., SmithKline Beecham Corporation, and Acorda Therapeutics, Inc.	Regis Technologies, Inc. SmithKline Beecham Corporation	-
251.	Master Service Agreement, dated as of May 5, 2009, by and between Acorda Therapeutics, Inc. and Regis Technologies Inc.	Regis Technologies Inc.	-
252.	Mutual Confidentiality and Non-Disclosure Agreement, dated as of October 1, 2009, by and among J-Star Research, Regis Technologies, Inc. and Acorda Therapeutics, Inc.	J-Star Research Regis Technologies, Inc.	-
253.	Project Addendum #10, dated as of July 25, 2011, by and	Regis Technologies Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Regis Technologies, Inc. and Acorda Therapeutics, Inc.		
254.	Project Addendum #11, dated as of March 6, 2012, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
255.	Project Addendum #2, dated as of March 9, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
256.	Project Addendum #3, dated as of May 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
257.	Project Addendum #4, dated as of August 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
258.	Project Addendum #5, dated as of August 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
259.	Project Addendum #6, dated as of September 15, 2009, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
260.	Project Addendum #8, dated as of May 7, 2010, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
261.	Project Addendum #9, dated as of April 6, 2011, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
262.	Project Addendum #9, dated as of September 27, 2010, by and	Regis Technologies Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Regis Technologies, Inc. and Acorda Therapeutics, Inc.		
263.	Quality Agreement, dated as of April 1, 2011, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
264.	Amendment #4 to Master Services Agreement, dated as of October 9, 2018, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
265.	Certificate of Analysis, dated as of April 1, 1987, prepared by Regis Technologies, Inc.	Regis Technologies Inc.	-
266.	Supply Agreement, dated as of April 1, 2011, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
267.	Amendment #5 to Master Services Agreement, dated as of January 29, 2024, by and between Regis Technologies, Inc. and Acorda Therapeutics, Inc.	Regis Technologies Inc.	-
268.	Letter Agreement on Confidential Treatment of Third Party Transaction Information, dated as of July 14, 2017, by and among Sharp Corporation, Alkermes Pharma Ireland Limited, and Acorda Therapeutics, Inc.	Sharp Corporation Alkermes Pharma Ireland Limited	-
269.	Four-Way Confidentiality Agreement dated as of July 18, 2017 between Acorda Therapeutics, Inc., Covis Pharma B.V., Alkermes Pharma Ireland Limited and Sharp Corporation	Covis Pharma B.V. Alkermes Pharma Ireland Limited Sharp Corporation	-
270.	Agreement on Confidential Treatment of Third Party Transaction Information, dated as of July 13, 2017, by and	Alkermes Pharma Ireland Limited	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Alkermes Pharma Ireland Limited and Acorda Therapeutics, Inc.		
271.	Letter Agreement on Subcontract of Certain Packaged Product Release and Quality Responsibilities by Alkermes to Acorda for Ampyra, Zanaflex and Tizanidine, dated as of May 5, 2016, by and between Alkermes Pharma Ireland Limited and Acorda Therapeutics, Inc.	Alkermes Pharma Ireland Limited	-
272.	Contract Packaging Quality Agreement, dated as of May 12, 2016, by and among Acorda Therapeutics, Inc., Sharp Corporation and Alkermes Pharma Ireland Limited	Alkermes Pharma Ireland Limited	-
273.	Confidential Disclosure Agreement, dated as of December 13, 2012, by and between Sharp Corporation and Acorda Therapeutics, Inc.	Sharp Corporation	-
274.	Packaging and Supply Agreement, dated as of December 31, 2016, by and between Acorda Therapeutics, Inc. and Sharp Packaging Services, LLC	Sharp Packaging Services, LLC	-
275.	Quality Agreement, dated as of October 16, 2017, by and between Acorda Therapeutics, Inc. and Sharp Corporation	Sharp Corporation	-
276.	First Amendment to the Packaging and Supply Agreement, dated as of December 13, 2022, by and between Sharp Packaging Services, LLC and Acorda Therapeutics, Inc.	Sharp Packaging Services, LLC	-
277.	Quality Agreement, dated as of November 28, 2018, by and	Qualicaps, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Qualicaps, Inc. and Acorda Therapeutics, Inc.		
278.	Amendment No. 1 to Commercial Quality Agreement, dated as of November 18, 2016, by and between Acorda Therapeutics, Inc. and Patheon, Inc.	Patheon, Inc.	-
279.	Change Order Pursuant to Section 9 of the Development and Manufacturing Services Agreement, dated as of June 18, 2015, by and between Acorda Therapeutics, Inc. and Patheon Biologics (NJ) LLC	Patheon Biologics (NJ) LLC	-
280.	Manufacturing Service Agreement, dated as of September 30, 2010, by and between Acorda Therapeutics, Inc. and Patheon Inc.	Patheon Inc.	-
281.	Master Agreement for Pharmaceutical Development Services, dated as of September 22, 2011, by and between Acorda Therapeutics, Inc. and Patheon Inc.	Patheon Inc.	-
282.	Change Order Pursuant to Section 9 of the Development and Manufacturing Services Agreement, dated as of September 14, 2015, by and between Acorda Therapeutics, Inc. and Patheon Biologics (NJ) LLC	Patheon Biologics (NJ) LLC	-
283.	Fampridine Tablets (10mg, 15mg, 20mg, 25mg) Technical Transfer Program Proposal for Commercial Registration, Proposal No. ELN-FQ-0001-1002-R4, dated as of February 26, 2003, by and between Patheon, Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
284.	Proposal SC_AA1_09032016-01 Additional Upstream	Patheon Biologics (NJ) LLC	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Process Development, dated as of August 26, 2016, by and between Patheon Biologics (NJ) LLC and Acorda Therapeutics, Inc.		
285.	Fampridine-SR Tablets: Validation Services Pricing Proposal and Terms and Conditions, Proposal #: 1707-FTR1-0400-0509-R0, dated as of September 14, 2009, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
286.	Ampyra 10 mg ER Tablets 2012 Annual Stability Studies, Proposal #: ACD-CTR1-05-0413-R0, dated as of June 17, 2013, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
287.	Ampyra 10 mg ER Tablets 2013 Annual Stability Studies – Lot MBZN made with 4-AP (Lot 234-35-2), Proposal #: ACD-CTR1-06-0513-R0, dated as of June 17, 2013, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
288.	Ampyra 10 mg ER Tables, 2015 Annual Stability Studies, Proposal #: ACD-CTR1-13-0615-R0, dated as of July 20, 2015, by and between Patheon Inc. and Acorda Therapeutics, Inc.	Patheon Inc.	-
289.	Quality Agreement Commercial Product, dated as of September 30, 2010, by and between Acorda Therapeutics, Inc. and Patheon Inc.	Patheon Inc.	-
290.	Manufacturing and Supply Agreement, dated as of January 16, 2020, by and between Acorda Therapeutics, Inc. and SMC Ltd.	SMC Ltd.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
291.	Amendment #1 to Manufacturing and Supply Agreement, dated as of March 31, 2020, by and between SMC, Ltd. and Acorda Therapeutics, Inc.	SMC, Ltd.	-
292.	Quality Agreement, dated as of June 2, 2021, by and between Acorda Therapeutics, Inc. and SMC Ltd.	SMC Ltd.	-
293.	Amendment #1 to Master Services Agreement, dated as of September 29, 2015, by and between The Hibbert Group and Acorda Therapeutics, Inc.	The Hibbert Group	-
294.	Amendment #2 to Master Services Agreement, dated as of October 25, 2018, by and between The Hibbert Group and Acorda Therapeutics, Inc.	The Hibbert Group	-
295.	Amendment #3 to Master Services Agreement, dated as of November 10, 2020, by and between The Hibbert Group and Acorda Therapeutics, Inc.	The Hibbert Group	-
296.	Quality Agreement, dated as of January 22, 2019, by and between Acorda Therapeutics, Inc. and the Hibbert Company Inc. d/b/a the Hibbert Group	The Hibbert Company Inc. d/b/a the Hibbert Group	-
297.	Master Service Agreement, dated as of September 18, 2014, by and between Acorda Therapeutics, Inc. and the Hibbert Company Inc. d/b/a the Hibbert Group	Hibbert Company Inc. d/b/a the Hibbert Group	\$25,848.70
298.	Amendment #4 to Master Services Agreement, dated as of January 31, 2024, by and between the Hibbert Company Inc. and Acorda Therapeutics, Inc.	The Hibbert Group	-
299.	Quality Agreement, dated as of October 12, 2021, by and	The Hibbert Group	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between The Hibbert Group and Acorda Therapeutics, Inc.		
300.	Quality Agreement, dated as of May 10, 2022, by and among Esteve Pharmaceuticals S.A., Esteve Pharmaceuticals GmbH and Acorda Therapeutics, Inc.	Esteve Pharmaceuticals S.A. Esteve Pharmaceuticals GmbH	-
301.	SC_AA1_09032016-01 Additional Upstream Process Development, dated as of August 26, 2016, by and between Patheon Biologics (NJ) LLC and Acorda Therapeutics, Inc.	Patheon Biologics (NJ) LLC	-
302.	Master Services Agreement, dated as of August 1, 2017, by and between Radius Product Development, Inc. and Acorda Therapeutics, Inc.	Radius Product Development, Inc.	-
303.	Amendment #1 to Master Services Agreement, dated as of July 26, 2019, by and between Radius Product Development, Inc. and Acorda Therapeutics, Inc.	Radius Product Development, Inc.	-
304.	Termination Letter, dated as of January 8, 2024, by and between Acorda Therapeutics, Inc. and Biogen International GMBH	Biogen International GMBH	-
305.	Transaction Document Form # M-4297, undated, by and between International Business Machines Corporation and Acorda Therapeutics, Inc.	International Business Machines Corporation	-
306.	Cloud Services Agreement, undated, by and between International Business Machines Corporation and Acorda Therapeutics, Inc.	International Business Machines Corporation	-
307.	Project Addendum #12, dated as of January 1, 2023, by and between Roadmap	Roadmap Technologies, Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Technologies, Inc. and Acorda Therapeutics, Inc.		
308.	Project Addendum #13, dated as of January 1, 2023, by and between Roadmap Technologies, Inc. and Acorda Therapeutics, Inc.	Roadmap Technologies, Inc.	-
309.	Master Service Agreement, dated as of April 29, 2014, by and between Acorda Therapeutics, Inc. and Roadmap Technologies, Inc.	Roadmap Technologies, Inc.	-
310.	Project Addendum #14, dated as of January 1, 2024, by and between Roadmap Technologies, Inc. and Acorda Therapeutics, Inc.	Roadmap Technologies, Inc.	-
311.	Project Addendum #15, dated as of January 1, 2024, by and between Roadmap Technologies, Inc. and Acorda Therapeutics, Inc.	Roadmap Technologies, Inc.	-
312.	Cooperation Agreement, dated as of May 10, 2022, by and between Acorda Therapeutics Ireland Limited and ACS PharmaProtect GmbH	ACS PharmaProtect GmbH	-
313.	Quality Agreement, dated as of August 1, 2022, by and between Acorda Therapeutics Ireland Limited and Adoh B.V.	Adoh B.V.	-
314.	General Service Agreement, dated as of October 16, 2018, by and between Acorda Therapeutics Ireland Limited and Adoh B.V.	Adoh B.V.	-
315.	Framework Agreement, dated as of March 3, 2023, by and between Ron Cohen in representation of Acorda Therapeutics Ireland Limited and Sistema Español de Verificacion de Medicamentos, S.L.	Sistema Español de Verificacion de Medicamentos, S.L.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
316.	Safety Agreement, dated as of June 2, 2020, by and between Acorda Therapeutics Ireland Limited and Adoh B.V.	Adoh B.V.	-
317.	Order Form, dated as of December 1, 2018, by and between Acorda Therapeutics, Inc. and Klick Inc.	Klick Inc.	-
318.	Order / Quote (Number: Q-28352), dated as of August 11, 2023, from Acorda Therapeutics, Inc. to Bigtincan Mobile Pty Ltd	Bigtincan Mobile Pty Ltd	-
319.	Omnicia Agreement, dated as of May 19, 2020, by and between Acorda Therapeutics, Inc. and Omnicia, Inc.	Omnicia, Inc.	-
320.	Confidential Disclosure Agreement, dated as of January 26, 2023, by and between Acorda Therapeutics, Inc. and Apollo Rx LLC	Apollo Rx LLC	-
321.	Project Addendum #1 to the Master Services Agreement, dated as of February 1, 2023, by and between Acorda Therapeutics, Inc. and Apollo Rx LLC	Apollo Rx LLC	-
322.	Master Services Agreement, dated as of February 1, 2023, by and between Acorda Therapeutics, Inc. and Apollo Rx LLC	Apollo Rx LLC	\$70,000.00
323.	Agreement for Authorised Representative Services, dated as of August 22, 2022, by and between Acorda Therapeutics, Inc. and Donawa Lifescience	Donawa Lifescience	-
324.	Master Services Agreement, dated as of October 30, 2018, by and between Acorda Therapeutics, Inc. and Clinipace, Inc. d/b/a Caidya	Clinipace, Inc. d/b/a Caidya	-
325.	Contract, dated as of March 1, 2023, by and between Acorda	BSI Group The Netherlands B.V.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	Therapeutics, Inc. and BSI Group The Netherlands B.V.		
326.	Master Consulting Agreement, dated as of August 19, 2021, by and between Acorda Therapeutics, Inc. and Gilani, LLC	Gilani, LLC	-
327.	Letter Agreement, dated as of April 14, 2021, by and between iPharma Labs, Inc. and Acorda Therapeutics, Inc.	iPharma Labs, Inc.	-
328.	Change Order No. 2 to the Original SOW, dated as of January 11, 2024, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	-
329.	Change Order No. 1 to the Original SOW, dated as of October 19, 2022, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	-
330.	Engagement Letter, dated as of January 7, 2021, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	-
331.	Mutual Nondisclosure Agreement, dated as of November 8, 2012, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	-
332.	Model N Business Services Statement of Work for Acorda Therapeutics, Inc., dated as of December 20, 2021, by and between Acorda Therapeutics, Inc. and Model N, Inc.	Model N, Inc.	-
333.	Co-Operation Agreement, dated as of March 25, 2024, by and among Acorda Therapeutics, Inc., RubiePharm Arzneimittel GmbH, Pharma Consulting Group, S.A. and Biopas Mexico, S.A. de C.V.	RubiePharm Arzneimittel GmbH Pharma Consulting Group, S.A. Biopas Mexico, S.A. de C.V.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
334.	Amendment #1 to Project Addendum #1, dated as of June 20, 2014, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC	Dohmen Life Science Services, LLC	-
335.	Amendment #1 to Project Addendum #3, dated as of September 13, 2016, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC as successor-in-interest to the The F. Dohmen Co.	Dohmen Life Science Services, LLC	-
336.	Amendment #2 to Project Addendum #3, dated as of November 6, 2018, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC as successor-in-interest to the The F. Dohmen Co.	Dohmen Life Science Services, LLC	-
337.	Amendment #3 to Project Addendum #3, dated as of March 28, 2019, by and between Acorda Therapeutics, Inc. and Eversana Life Science Services, LLC (formerly known as Dohmen Life Science Services, LLC)	Eversana Life Science Services, LLC (formerly known as Dohmen Life Science Services, LLC)	\$107,604.04
338.	Assignment and Assumption Agreement, dated as of June 20, 2014, by and between The F. Dohmen Co. and Dohmen Life Science Services, LLC, and consented to by Acorda Therapeutics, Inc.	The F. Dohmen Co. Dohmen Life Science Services, LLC	-
339.	Master Services Agreement, dated as of March 22, 2013, by and between Acorda Therapeutics, Inc. and The F. Dohmen Co. (d/b/a MedComm Solutions)	The F. Dohmen Co. (d/b/a MedComm Solutions)	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
340.	Project Addendum #1, dated as of March 22, 2013, by and between Acorda Therapeutics, Inc. and The F. Dohmen Co. (d/b/a MedComm Solutions)	The F. Dohmen Co. (d/b/a MedComm Solutions)	-
341.	Project Addendum #2, dated as of March 3, 2015, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC	Dohmen Life Science Services, LLC	-
342.	Project Addendum #3, dated as of January 1, 2016, by and between Acorda Therapeutics, Inc. and Dohmen Life Science Services, LLC	Dohmen Life Science Services, LLC	-
343.	Settlement Agreement, dated as of January 12, 2018, by and between Acorda Therapeutics, Inc. and Micro USA Inc.	Micro USA Inc.	-
344.	Settlement Agreement, dated as of January 12, 2018, by and between Acorda Therapeutics, Inc. and Actavis Laboratories FL, Inc.	Actavis Laboratories FL, Inc.	-
345.	Settlement Agreement, dated as of December 15, 2015, by and between Acorda Therapeutics, Inc. and Aurobindo Pharma USA.	Aurobindo Pharma USA.	-
346.	Settlement Agreement, dated as of February 8, 2017, by and between Acorda Therapeutics, Inc. and Apotex Inc.	Apotex Inc.	-
347.	Settlement Agreement, dated as of August 11, 2016, by and between Acorda Therapeutics, Inc. and Accord Healthcare, Inc.	Accord Healthcare, Inc.	-
348.	Settlement Agreement, dated as of January 15, 2016, by and between Acorda Therapeutics, Inc. and Par Pharmaceuticals Inc.	Par Pharmaceuticals Inc.	-
349.	Settlement Agreement, dated as of July 27, 2018, by and	Mylan Inc.	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
	between Acorda Therapeutics, Inc. and Mylan Inc.		
350.	Settlement Agreement, dated as of October 15, 2015, by and between Acorda Therapeutics, Inc. and Sun Pharmaceuticals Industries Limited.	Sun Pharmaceuticals Industries Limited.	-
351.	Inbrija® Ambassador Program Agreement, dated May 17, 2021, by and between Acorda Therapeutics, Inc. and Rachel Weinberger, as amended.	Rachel Weinberger	-
352.	Inbrija® Ambassador Program Agreement, dated September 27, 2019, by and between Acorda Therapeutics, Inc. and Stephanie Cook, as amended	Stephanie Cook	-
353.	Inbrija™ Ambassador Program Agreement, dated November 6, 2019, by and between Acorda Therapeutics, Inc. and John Baumann.	John Baumann	-
354.	Inbrija® Ambassador Program Agreement, dated April 6, 2020, by and between Acorda Therapeutics, Inc. and James Gaddis, as amended.	James Gaddis	-
355.	Inbrija® Ambassador Program Agreement, dated September 6, 2019, by and between Acorda Therapeutics, Inc. and Robert Harmon, as amended.	Robert Harmon	-
356.	INBRIJA™ Ambassador Program Agreement dated September 9, 2019, as amended	Bettina Chavanne	-
357.	INBRIJA® Patient Video Program Agreement dated October 2, 2023	Kay Henry	-
358.	Care Partner Agreement dated October 2, 2023	Charles Henry	-
359.	INBRIJA® Care Partner Program Agreement dated June 3, 2022, as amended	Kristi Gaddis	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
360.	INBRIJA® Care Partner Program Agreement dated June 6, 2022	Bernadette Baumann	-
361.	Authorization to Reproduce Video and Likeness Release dated October 6, 2019 signed by Cecily Harmon	Cecily Harmon	-
362.	Master Consulting Agreement, dated September 12, 2016, by and between Acorda Therapeutics, Inc. and Gary Rafaloff, as amended.	Gary Rafaloff	-
363.	Master Consulting Agreement, dated July 2, 2015, by and between Acorda Therapeutics, Inc. and Peter LeWitt, as amended. Master Consulting Agreement, dated June 1, 2020, by and between Acorda Therapeutics, Inc. and Peter A. LeWitt, MD, as amended.	Peter LeWitt	-
364.	Master Consulting Agreement, dated as of January 12, 2021, by and between Acorda Therapeutics, Inc. and Julie Schwartzbard, MD, as amended.	Julie Schwartzbard	-
365.	Master Consulting Agreement, dated as of January 15, 2021, by and between Acorda Therapeutics, Inc. and Jennifer Durphy, as amended.	Jennifer Durphy	\$650.00
366.	Master Consulting Agreement, dated as of September 10, 2020, by and between Acorda Therapeutics, Inc. and Ray Dorsey, MD, as amended.	Ray Dorsey	-
367.	Master Consulting Agreement, dated as of September 10, 2020, by and between Acorda Therapeutics, Inc. and Rajeev Kumar, MD, as amended.	Rajeev Kumar	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
368.	Master Consulting Agreement, dated as of November 25, 2020, by and between Acorda Therapeutics, Inc. and Ronald F. Pfeiffer, as amended.	Ronald Pfeiffer	-
369.	Master Consulting Agreement, dated as of December 3, 2020, by and between Acorda Therapeutics, Inc. and Dr. Salima Brillman, as amended.	Salima Brillman	-
370.	<ul style="list-style-type: none"> Letter agreement titled "Re: Letter regarding Services for Presentation for Consumer Programs for Ampyra ("Letter")", dated as of May 11, 2010, by Acorda Therapeutics, Inc. and acknowledged by Susan Zurndorfer. Consulting Agreement, dated as of May 10, 2007, by and between Acorda Therapeutics, Inc. and Susan Zurndorfer. Letter agreement titled "Re: Letter for Services for Photograph ("Letter")", dated as of March 7, 2011, by Acorda Therapeutics, Inc. and acknowledged by Susan Zurndorfer. Master Consulting Agreement, dated as of March 25, 2013, by and between Acorda Therapeutics, Inc. and Susan Zurndorfer, as amended. 	Susan Zurndorfer	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
371.	<ul style="list-style-type: none"> • Parent's or Guardian's Consent, dated as of February 1, 2012, by Lisa Green • Letter agreement titled "Re: Letter Agreement for Participation in Patient Testimonials, an Audio News Releases and a Matte Release", dated as of August 17, 2011, by Acorda Therapeutics, Inc. and acknowledged by Lisa Green. • Letter agreement titled "Re: Letter Agreement for Participation in Patient Testimonials, an Audio News Releases and a Matte Release", dated as of September 7, 2012, by Acorda Therapeutics, Inc. and acknowledged by Lisa Green. 	Lisa Green	-
372.	Non-Healthcare Professional Ambassador Agreement, dated January 1, 2020, by and between Acorda Therapeutics, Inc. and Zarela Martinez, as amended	Zarela Martinez	-
373.	Non-Healthcare Professional Consulting Agreement dated September 5, 2018	Sarah Diaz	-
374.	Non-Healthcare Professional Consulting Agreement dated January 9, 2019	Gustavo Pavon	-
375.	Non-Healthcare Professional Consulting Agreement dated January 9, 2019	Linda Berghoff	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
376.	Non-Healthcare Professional Consulting Agreement, dated September 5, 2018, by and between Acorda Therapeutics, Inc. and John Pelchat.	John Pelchat	-
377.	Non-Healthcare Professional Consulting Agreement, dated September 5, 2018, by and between Acorda Therapeutics, Inc. and Jennifer Parkinson	Jennifer Parkinson	-
378.	Non-Healthcare Professional Consulting Agreement, dated September 5, 2018, by and between Acorda Therapeutics, Inc. and Steve Peters.	Steve Peters	-
379.	Consultant Agreement (Non-HCP), dated June 1, 2016, by and between Acorda Therapeutics, Inc. and Lynn Hagerbrant, as amended.	Lynn Hagerbrant	-
380.	Non-Healthcare Professional Consulting Agreement, dated February 8, 2018, by and between Acorda Therapeutics, Inc. and Michael Bergamo.	Michael Bergamo	-
381.	<ul style="list-style-type: none"> Consultant Agreement (Non-HCP), dated June 30, 2016, by and between Acorda Therapeutics, Inc. and Brenda Vanesse, as amended. Non-Healthcare Professional Consulting Agreement, dated June 21, 2018, by and between Acorda Therapeutics, Inc. and Brenda Vanesse. 	Brenda Vanesse	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
382.	<ul style="list-style-type: none"> • Consultant Agreement (Non-HCP), dated June 8, 2016, by and between Acorda Therapeutics, Inc. and Steven DeWitte. • Non-Healthcare Professional Consulting Agreement, dated January 16, 2018, by and between Acorda Therapeutics, Inc. and Steven DeWitte. • Non-Healthcare Professional Consulting Agreement, dated August 10, 2018, by and between Acorda Therapeutics, Inc. and Steven DeWitte. 	Steven DeWitte	-
383.	<ul style="list-style-type: none"> • Patient Consultant Agreement (Non-HCP), dated April 4, 2016, by and between Acorda Therapeutics, Inc. and Gary Rafaloff. • Non-Healthcare Professional Consulting Agreement, dated June 21, 2018, by and between Acorda Therapeutics, Inc. and Gary Rafaloff. 	Gary Rafaloff	-
384.	Healthcare Professional Advisory Board Consulting Agreement, dated as of November 13, 2018, by and between Acorda Therapeutics, Inc. and Rajeev Kumar, MD, FRCPC, as amended.	Rajeev Kumar	-

No.	Contract	Counter Party(s)	Cure Amount (\$)
385.	GI Dysfunction in Patients with Parkinson's Disease Video Consulting, dated as of May 13, 2019, by and between Acorda Therapeutics, Inc. and Ronald F. Pfeiffer, MD, as amended.	Ronald Pfeiffer	-

Exhibit C

Exhibit C
Assumption Counterparties Service List
Served via overnight mail

AddressID	Name	Address1	Address2	Address3	City	State	Postal Code	Country
28616849	ACCORD HEALTHCARE, INC.	ATTN: PRESIDENT	1009 SLATER ROAD		DURHAM	NC	27703	
28618959	ACCREDITO HEALTH GROUP, INC.	1 EXPRESS WAY, ATTN: ANDREW CARRON HQ2EO4			ST LOUIS	MO	63121	
28617110	ACCREDITO HEALTH GROUP, INC.	13408 COLLECTION CENTER DRIVE			CHICAGO	IL	60693	
28616851	ACCREDITO HEALTH GROUP, INC.	6272 LEE VISTA BLVD			ORLANDO	FL	32822	
28618054	ACS PHARMAPROTECT GMBH	TAUBENSTRASSE 20			BERLIN		10117	DE
28616854	ACTAVIS LABORATORIES FL, INC.	ATTN: CHIEF LEGAL OFFICER	MORRIS CORPORATE CENTER III	400 INTERPADE PARKWAY	PARSIPPANY	NJ	07054	
28616856	ADOH B.V.	ATTN: SJENG HOVENS, DIRECTOR	GODFRIED BOMANSSTRAAT 31		NIJMEGEN, NL		6543 JA	NL
28616860	ALKERMES PHARMA IRELAND LIMITED	CONNAUGHT HOUSE 1,BURLINGTON ROAD			DUBLIN			IE
28618072	ALKERMES PHARMA IRELAND LIMITED	MONKSLAND INDUSTRIAL ESTATE			ATHLONE, COUNTY WESTMEATH		N37 EA09	IE
28619230	ALKERMES, INC.	88 SIDNEY STREET			CAMBRIDGE	MA	02139-4136	
28618073	ALKERMES, INC.	900 WINTER STREET			WALTHAM	MA	02451	
28616861	ALKERMES, INC.	ATTN: CHIEF EXECUTIVE OFFICER	384 POWDER MILL ROAD		CONCORD	MA	01742	
28616864	AMERISOURCEBERGEN DRUG CORPORATION	ATTN: CHIEF PROCUREMENT OFFICE	1300 MORRIS DRIVE		CHESTERBROOK	PA	19087	
28618112	AMERISOURCEBERGEN DRUG CORPORATION	PO BOX 247, ATTN: RETURNS DEPARTMENT			THOROFARE	NJ	08086	
28619524	APOLLO RX LLC	ATTN: DAN WALLENBERG, CHIEF COMMERCIAL OFFICER	150 N RIVERSIDE PLAZA	SUITE 3400	CHICAGO	IL	60606	
28616867	APOLLO RX, LLC	150 N RIVERSIDE PLAZA SUITE 3400			CHICAGO	IL	60606	
28616868	APOTEX INC.	ATTN: ROBERT SHAPIRO	150 SIGNET DRIVE		TORONTO	ON	M9L 1T9	CA
28616871	ASCENT HEALTH SERVICES LLC	ATTN: GENERAL COUNSEL	C/O WADSACK SCHAFFHAUSEN AG	OBERSTADT 3	SCHAFFHAUSEN		8200	CH
28618961	ASD SPECIALTY HEALTHCARE, INC.	1 WEST FIRST AVENUE, ATTN: ACCTS PAYABLE			CONSHOHOCKEN	PA	19428	
28616874	ASD SPECIALTY HEALTHCARE, INC.	345 INTERNATIONAL BLVD. SUITE 400			BROOKS	KY	40109	
28616873	ASD SPECIALTY HEALTHCARE, INC.	ATTN: PRESIDENT	3101 GAYLORD PARKWAY		FRISCO	TX	75034	
28617115	ASD SPECIALTY HEALTHCARE, INC.	PO BOX 676217			DALLAS	TX	75267-6217	
28873243	ASD SPECIALTY HEALTHCARE, LLC	101 NORFOLK ST STE B			MANSFIELD	MA	02048-1833	
28873244	ASD SPECIALTY HEALTHCARE, LLC	5025 PLANO PKWY			CARROLLTON	TX	75010	
28616876	AUROBINDO PHARMA USA	ATTN: ROBERT CUNARD	6 WHEELING ROAD		DAYTON	NJ	08810	
28873112	BAUMANN, BERNADETTE	ADDRESS ON FILE						
28873149	BAUMANN, JOHN	ADDRESS ON FILE						
28873111	BAYER HEALTHCARE PHARMACEUTICALS INC.	100 BAYER BLVD.			WHIPPANY	NJ	07981	

Exhibit C
Assumption Counterparties Service List
Served via overnight mail

AddressID	Name	Address1	Address2	Address3	City	State	Postal Code	Country
28873158	BERGAMO, MICHAEL	ADDRESS ON FILE						
28873155	BERGHOFF, LINDA	ADDRESS ON FILE						
28616883	BIGTINCAN MOBILE PTY LTD	L9 257 CLARENCE ST			SYDNEY, NSW		2000	AU
28618158	BIGTINCAN MOBILE PTY LTD	LEVEL 6, 338 PITT STREET			SYDNEY, NSW		2000	AU
28616885	BIOGEN IDEC INTERNATIONAL GMBH	ATTN: FRANCIS MARSLAND	LANDIS & GYR STRASSE 3		ZUG		CH-6300	CH
28617586	BIOGEN INTERNATIONAL GMBH	LANDIS & GYR STRASSE 3, ATTN: FRANCIS MARSLAND			ZUG		6300	CH
28873114	BIOPAS MEXICO,S.A. DE C.V.	ATTN: MIGUEL HIDALGO	BLVD. MANUEL ÁVILA CAMACHO NO. 76	PISO 2 LOMAS DE CHAPULTEPEC V SECC.	CIUDAD DE MEXICO		11000	MX
28617514	BONACUM, ALEX	ADDRESS ON FILE						
28873168	BRILLMAN, SALIMA	ADDRESS ON FILE						
28617118	BRIOVARX OF MAINE, INC	1600 MCCONNOR PARKWAY			SCHAUMBURG	IL	60173	
28616887	BRIOVARX OF MAINE, INC	ATTN: S.V.P AND GENERAL COUNSEL	5995 PLAZA DR M/S CA112-0567		CYPRESS	CA	90630	
28618963	BRIOVARX OF MAINE, INC	CATAMARAN LLC, PO BOX 998, ATTN: ACCOUNTS PAYABLE			MISSION	KS	66201	
28873131	BRODSKY, DENNIS	ADDRESS ON FILE						
28616889	BSI GROUP THE NETHERLANDS B.V.	SAY BUILDING, JOHN M. KEYNESPLEIN 9			AMSTERDAM		1066 EP	NL
28616893	CARDINAL HEALTH 105, INC.	15 INGRAM BOULEVARD SUITE 100			LA VERGNE	TN	37086	
28616892	CARDINAL HEALTH 105, INC.	501 MASON ROAD SUITE 200			LA VERGNE	TN	37086	
28618195	CARDINAL HEALTH 105, INC.	PO BOX 978709			DALLAS	TX	75397-8709	
28873116	CARDINAL HEALTH 105, INC. F.K.A. CARDINAL HEALTH PTS, LLC	15 INGRAM BOULEVARD SUITE 100			LA VERGNE	TN	37086	
28873117	CARDINAL HEALTH 105, INC. F.K.A. CARDINAL HEALTH PTS, LLC	501 MASON ROAD SUITE 200			LA VERGNE	TN	37086	
28873118	CARDINAL HEALTH 105, INC. F.K.A. CARDINAL HEALTH PTS, LLC	PO BOX 978709			DALLAS	TX	75397-8709	
28873119	CARDINAL HEALTH 110, INC.	15 INGRAM BOULEVARD SUITE 100			LA VERGNE	TN	37086	
28873120	CARDINAL HEALTH 110, INC.	501 MASON ROAD SUITE 200			LA VERGNE	TN	37086	
28873121	CARDINAL HEALTH 110, INC.	PO BOX 978709			DALLAS	TX	75397-8709	
28873122	CARDINAL HEALTH PTS, LLC	15 INGRAM BOULEVARD SUITE 100			LA VERGNE	TN	37086	
28873123	CARDINAL HEALTH PTS, LLC	501 MASON ROAD SUITE 200			LA VERGNE	TN	37086	
28873124	CARDINAL HEALTH PTS, LLC	PO BOX 978709			DALLAS	TX	75397-8709	
28873125	CARDINAL HEALTH SPECIALTY SOLUTIONS	15 INGRAM BOULEVARD SUITE 100			LA VERGNE	TN	37086	
28873126	CARDINAL HEALTH SPECIALTY SOLUTIONS	501 MASON ROAD SUITE 200			LA VERGNE	TN	37086	
28873127	CARDINAL HEALTH SPECIALTY SOLUTIONS	PO BOX 978709			DALLAS	TX	75397-8709	

Exhibit C
Assumption Counterparties Service List
Served via overnight mail

AddressID	Name	Address1	Address2	Address3	City	State	Postal Code	Country
28619549	CAREMARK L.L.C.	ATTN: BRADLEY KRUK, MANAGER, TRADE SERVICES	2211 SANDERS ROAD 8TH FLOOR		NORTHBROOK	IL	60062	
28616895	CAREMARK, L.L.C.	ATTN: DIRECTOR, INDUSTRY RELATIONS	2211 SANDERS ROAD		NORTHBROOK	IL	60062	
28616894	CAREMARK, L.L.C.	ATTN: SENIOR DIRECTOR, SPECIALTY TRADE RELATIONS	2211 SANDERS ROAD	8TH FLOOR	NORTHBROOK	IL	60062	
28618197	CAREMARK, L.L.C.	PO BOX 848143, 1950 N. STEMMONS FWY.			DALLAS	TX	75207	
28618969	CAREMARKPCS HEALTH L.L.C	9501 E SHEA BLVD MC 141, ATTN: DATA MANAGEMENT- MC 141 ACCOUNTS PAYABLE			SCOTTSDALE	AZ	85260	
28616896	CAREMARKPCS HEALTH L.L.C	ATTN: SENIOR VICE PRESIDENT, TRADE RELATIONS	2211 SANDERS ROAD		NORTHBROOK	IL	60062	
28617120	CAREMARKPCS HEALTH L.L.C	ONE CVS DRIVE, MAIL CODE 2250			WOONSOCKET	RI	02895	
28618202	CATALENT MASSACHUSETTS LLC	14 SCHOOLHOUSE ROAD			SOMERSET	NJ	08873	
28619514	CATALENT MASSACHUSETTS LLC	ATTN: GENERAL COUNSEL (LEGAL DEPARTMENT)	14 SCHOOLHOUSE ROAD		SOMERSET	NJ	08873	
28618205	CATALENTPHARMA SOLUTIONS	14 SCHOOLHOUSE ROAD			SOMERSET	NJ	08873	
28873113	CHAVANNE, BETTINA	ADDRESS ON FILE						
28873130	CLINIPACE, INC. D/B/A CAIDYA	3800 PARAMOUNT PKWY, STE 100			MORRISVILLE	NC	27560	
28873173	COOK, STEPHANIE	ADDRESS ON FILE						
28616911	COVANCE MARKET ACCESS SERVICES INC.	9801 WASHINGTON BLVD, NINTH FLOOR, ATTN: GENERAL MANAGER			GAITHERSBURG	MD	20878	
28618254	COVANCE MARKET ACCESS SERVICES INC.	PO BOX 2494			BURLINGTON	NC	27216	
28617131	COVANCE SPECIALTY PHARMACY, LLC	PO BOX 2494			BURLINGTON	NC	27216	
28616912	COVIS PHARMA BV	BAHNHOFSTRASSE 11			ZUG		CH-6300	CH
28617133	CVS CAREMARK PART D SERVICES, LLC	2211 SANDERS ROAD NBT-8			NORTHBROOK	IL	60062	
28616913	CVS CAREMARK PART D SERVICES, LLC	2211 SANDERS ROAD, ATTN: DIRECTOR, INDUSTRY ANALYSIS			NORTHBROOK	IL	60062	
28873175	DEWITTE, STEVEN	ADDRESS ON FILE						
28873169	DIAZ, SARAH	ADDRESS ON FILE						
28873132	DOHMEN LIFE SCIENCE SERVICES, LLC	24740 NETWORK PLACE			CHICAGO	IL	60673-1247	
28873133	DONAWA LIFESCIENCE	AGENZIA N.19 PIAZZA ALBANIA, 11C			ROME		00153	IT
28873134	DONAWA LIFESCIENCE	PIAZZA ALBANIA, 10			ROME		00153	IT
28873165	DORSEY, RAY	ADDRESS ON FILE						
28873147	DURPHY, JENNIFER	ADDRESS ON FILE						

Exhibit C
Assumption Counterparties Service List
Served via overnight mail

AddressID	Name	Address1	Address2	Address3	City	State	Postal Code	Country
28616928	ELIXIR RX SOLUTIONS OF NEVADA, LLC	1100 INVESTMENT BLVD., ATTN: TRADE RELATIONS			ELDORADO HILLS	CA	95762	
28873135	ESTEVE PHARMACEUTICALS GMBH	ATTN: CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICE	TORRE ESTEVE PASSEIGE DE LA ZONA FRANCA 109		BARCELONA		08038	ES
28616933	ESTEVE PHARMACEUTICALS GMBH	ATTN: MANAGING DIRECTOR HOHENZOLLERN DAMN 150-151			BERLIN		14199	DE
28618327	ESTEVE PHARMACEUTICALS GMBH	SITE BERLIN HOHENZOLLERN DAMM 150 - 151			BERLIN		14199	DE
28873138	ESTEVE PHARMACEUTICALS S.A.	ATTN: CORPORATE STRATEGY & BUSINESS DEVELOPMENT OFFICE	TORRE ESTEVE PASSEIGE DE LA ZONA FRANCA 109		BARCELONA		08038	ES
28873136	ESTEVE PHARMACEUTICALS S.A.	ATTN: MANAGING DIRECTOR	HOHENZOLLERN DAMN 150-151		BERLIN		14199	DE
28873137	ESTEVE PHARMACEUTICALS S.A.	SITE BERLIN HOHENZOLLERN DAMM 150 - 151			BERLIN		14199	DE
28873139	EVERSANA LIFE SCIENCE SERVICES, LLC	(FORMERLY KNOWN AS DOHMEN LIFE SCIENCE SERVICES, LLC)	24740 NETWORK PLACE		CHICAGO	IL	60673-1247	
28616935	EXPRESS SCRIPTS SENIOR CARE HOLDINGS, INC.	ONE EXPRESS WAY, ATTN: EDWARD J. ADAMCIK			SAINT LOUIS	MO	63121	
28616936	EXPRESS SCRIPTS, INC.	ONE EXPRESS WAY, ATTN: DIRECTOR, PHARMACY STRATEGY & CONTRACTING			SAINT LOUIS	MO	63121	
28618970	FORTREA SPECIALTY PHARMACY, LLC	100 TECHNOLOGY PARK STE 158, ATTN: HEIDI HUYNH			LAKE MARY	FL	32746	
28616940	FORTREA SPECIALTY PHARMACY, LLC	ATTN: CONTRACTS MANAGEMENT 8 MOORE DRIVE			DURHAM	NC	27709	
28618361	FORTREA SPECIALTY PHARMACY, LLC	PO BOX 931364			ATLANTA	GA	31193-1364	
28873146	GADDIS, JAMES	ADDRESS ON FILE						
28873154	GADDIS, KRISTI	ADDRESS ON FILE						
28616943	GENTRY HEALTH SERVICES INC.	211 COMMERCE DRIVE, ATTN: LEGAL			MEDINA	OH	44256	
28617138	GENTRY HEALTH SERVICES INC.	33381 WALKER ROAD, SUITE A			AVON LAKE	OH	44012	
28618379	GILANI, LLC	117 WEST PLAIN STREET, ATTN: FAHAD SYED GILANI			WAYLAND	MA	01778	
28873156	GREEN, LISA	ADDRESS ON FILE						
28873157	HAGERBRANT, LYNN	ADDRESS ON FILE						

Exhibit C
Assumption Counterparties Service List
Served via overnight mail

AddressID	Name	Address1	Address2	Address3	City	State	Postal Code	Country
28616950	HANGZHOU CHANCE PHARMACEUTICALS CO. LTD	BUILDING C 7 LONGTAN RD.			YUHANG, HANGZHOU ZHEJIANG		311121	CN
28873128	HARMON, CECILY	ADDRESS ON FILE						
28873166	HARMON, ROBERT	ADDRESS ON FILE						
28873129	HENRY, CHARLES	ADDRESS ON FILE						
28873153	HENRY, KAY	ADDRESS ON FILE						
28873142	HIBBERT COMPANY INC. D/B/A THE HIBBERT GROUP	ATTN: OKSANA POSEWA	400 PENNINGTON AVENUE		TRENTON	NJ	08618	
28873143	HIBBERT COMPANY INC. D/B/A THE HIBBERT GROUP	LBX 41765 PO BOX 8500			PHILADELPHIA	PA	19178	
28616959	HUMANA PHARMACY, INC.	ATTN: ADAM HANAUER 111 MERCHANT STREET			CINCINNATI	OH	45426	
28616958	HUMANA PHARMACY, INC.	ATTN: LAW DEPARTMENT 500 WEST MAIN STREET			LOUISVILLE	KY	40202	
28618417	HUMANA PHARMACY, INC.	PO BOX 747, ATTN: ACCOUNTS PAYABLE 044/7445			CINCINNATI	OH	45201	
28873144	INTERNATIONAL BUSINESS MACHINES CORPORATION	1 NEW ORCHARD ROAD			ARMONK	NY	10504-1722	
28873145	IPHARMA LABS, INC.	32930 ALVADARA-NILES ROAD, SUITE 350			UNION CITY	CA	94587	
28873151	J-STAR RESEARCH	3001 HADLEY RD.			SOUTH PLAINFIELD	NJ	07080	
28616970	KAISER FOUNDATIONS HOSPITALS AND KAISER FOUNDATION HEALTH PLAN, INC.	300 PULLMAN STREET, ATTN: DIRECTOR, PHARMACY CONTRACTING			LIVERMORE	CA	94551	
28616974	KLICK INC.	175 BLOOR STREET EAST NORTH TOWER SUITE 301			TORONTO	ON	M4W 3R8	CA
28873164	KUMAR, RAJEEV	ADDRESS ON FILE						
28618494	LABCORP PERI-APPROVAL AND COMMERCIALIZATION INC.	PO BOX 2494			BURLINGTON	NC	27216	
28617142	LABCORP SPECIALTY PHARMACY LLC	PO BOX 2494			BURLINGTON	NC	27216	
28873160	LEWITT, PETER	ADDRESS ON FILE						
28873161	LEWITT, PETER	ADDRESS ON FILE						
28873188	MARTINEZ, ZARELA	ADDRESS ON FILE						
28616982	MAYNE PHARMA, INC.	1240 SUGG PARKWAY, ATTN: PRESIDENT			GREENVILLE	NC	27834	
28617143	MCKESSON CORPORATION	ONE POST STREET, 21ST FLOOR			SAN FRANCISCO	CA	94104	
28618537	MEDENVOY GLOBAL BV	WTC THE HAGUE PRINSES MARGRIETPLANTSOEN 33 SUITE 123, ATTN: MS. BIRGIT HOLL			THE HAGUE		2595	NL

Exhibit C
Assumption Counterparties Service List
Served via overnight mail

AddressID	Name	Address1	Address2	Address3	City	State	Postal Code	Country
28618544	MERCALIS INC.	2250 PERIMETER PARK DRIVE, SUITE 300, ATTN: MARK BOUCK			MORRISVILLE	NC	27560	
28616991	METRICS, INC.	1240 SUGG PARKWAY, ATTN: PRESIDENT			GREENVILLE	NC	27834	
28616996	MICRO USA INC.	100 S. WACKER DRIVE, ATTN: SHASHANK UPADHYE			CHICAGO	IL	60606	
28618564	MODEL N, INC.	777 MARINERS ISLAND BLVD. SUITE #300			SAN MATEO	CA	94404	
28616997	MYLAN INC.	1000 MYLAN BOULEVARD, ATTN: LEGAL DEPARTMENT			CANONSBURG	PA	15317	
28617000	NAVITUS HEALTH SOLUTIONS, LLC	361 INTEGRITY DRIVE			MADISON	WI	53717	
28873159	NDA GROUP AB	NEUMARKTER STRASSE 18			MUNICH		81673	DE
28618623	OMNICIA, INC.	50 CALIFORNIA STREET SUITE 1508			SAN FRANCISCO	CA	94111	
28617011	OMNICIA, INC.	ATTN: REUBEN K. JENKINS ONE MARKET STREET SPEAR TOWER 36TH FLOOR			SAN FRANCISCO	CA	94105	
28617013	OPTUMRX, INC.	ATTN: S.V.P CHIEF PHARMA CONTACTING AND PROCUREMENT OFFICER	2300 MAIN STREET M/S CA134- 0509,		IRVINE	CA	92614	
28617515	OPUS REGULATORY, INC.	245 1ST STREET, 18TH FLOOR			CAMBRIDGE	MA	02142	
28618630	OPUS REGULATORY, INC.	245 1ST STREET, 18TH FLOOR, ATTN: ANDREA BOHN			CAMBRIDGE	MA	02142	
28617015	OPUS REGULATORY, INC.	ATTN: ANDREA BOHN 245 1ST STREET 18TH FLOOR			CAMBRIDGE	MA	02142	
28617020	PAR PHARMACEUTICALS INC.	420 SAW MILL RIVER ROAD, ATTN: GENERAL COUNSEL			ARDSLEY	NY	10502	
28873148	PARKINSON, JENNIFER	ADDRESS ON FILE						
28617021	PATHEON BIOLOGICS (NJ), LLC	201 COLLEGE RD			EAST PRINCETON	NJ	08540	
28618976	PATHEON, INC.	111 CONSUMERS DRIVE			WHITBY	ON	L1N 5Z5	CA
28617022	PATHEON, INC.	2100 SYNTEX COURT, ATTN: GENERAL COUNSEL			MISSISSAUGA	ON	L5N 7K9	CA
28618672	PATHEON, INC.	PO BOX 74007046			CHICAGO	IL	60674-7046	
28873141	PAVON, GUSTAVO	ADDRESS ON FILE						
28873150	PELCHAT, JOHN	ADDRESS ON FILE						
28873176	PETERS, STEVE	ADDRESS ON FILE						
28873167	PFEIFFER, RONALD	ADDRESS ON FILE						
28617023	PHARMA CONSULTING GROUP S.A	ATTN: PASCAL FORGET, PRESIDENT & CEO	CALLE 47 AQUILINO DE LA GUARDIA	EDIFICIO OCEAN PLAZA - PISO 17 OF 11	PANAMA			PA
28873162	PHARMACOVIGILANCE PHYSICIAN SERVICES LLC	PO BOX 11087			ERIE	PA	16514	

Exhibit C
Assumption Counterparties Service List
Served via overnight mail

AddressID	Name	Address1	Address2	Address3	City	State	Postal Code	Country
28617028	QUALICAPS INC.	6505 FRANZ WORNER PARKWAY			WHITSETT	NC	27377	
28618994	RADIUS PRODUCT DEVELOPMENT INC.	200 UNION STREET			CLINTON	MA	01510	
28618717	RADIUS PRODUCT DEVELOPMENT INC.	C/O NYPRO INC., 28748 NETWORK PLACE			CHICAGO	IL	60673-1287	
28873140	RAFALOFF, GARY	ADDRESS ON FILE						
28617037	REGIS TECHNOLOGIES, INC.	8210 AUSTIN AVENUE			MORTON GROVE	IL	60053	
28618730	REGIS TECHNOLOGIES, INC.	PO BOX 7222			CAROL STREAM	IL	60197-7222	
28617039	RIPARIAN, LLC	110 RIVERBEND AVENUE SUITE 100, ATTN: DAVID CHAN			POWELL	OH	43065	
28618740	RIPARIAN, LLC	PO BOX 933205			CLEVELAND	OH	44193	
28618741	RIS RX	351 HOSPITAL ROAD, SUITE 306, ATTN: LEGAL DEPARTMENT			NEWPORT BEACH	CA	92663	
28617040	RIS RX	351 HOSPITAL ROAD, SUITE 306, ATTN: LEGAL DEPARTMENT			NEWPORT	CA	92663	
28617041	ROADMAP TECHNOLOGIES, INC.	100 CUMMINGS CENTER, ATTN: LEGAL DEPARTMENT			BEVERLY	MA	01915	
28618744	ROADMAP TECHNOLOGIES, INC.	PO BOX 7023			BEVERLY	MA	01915	
28617045	NAME ON FILE	ADDRESS ON FILE						
28617472	SA GLOBAL SOLUTIONS, LLC	ADDRESS ON FILE						
28617538	SA GLOBAL SOLUTIONS, LLC	418 BROADWAY, STE N			ALBANY	NY	12207	
28873152	SCHWARTZBARD, JULIE	ADDRESS ON FILE						
28618996	SCIENTIFIC RESEARCH PARTNERS, LLC	ATTN: JUERGEN PFEIFFER	PO BOX 87		MOSS BEACH	CA	94038	
28617056	SHARP CORPORATION	7451 KEEBLER WAY, ATTN: CFO			ALLENTOWN	PA	18106	
28619523	SHARP CORPORATION	ATTN: BARBARA OST, VICE PRESIDENT	7451 KEEBLER WAY		ALLENTOWN	PA	18106	
28618781	SHARP CORPORATION	PO BOX 786245			PHILADELPHIA	PA	19178	
28873170	SHARP PACKAGING SERVICES, LLC	PO BOX 786245			PHILADELPHIA	PA	19178	
28873171	SISTEMA ESPAÑOL DE VERIFICACION DE MEDICAMENTOS, S.L.	ATTN: MARIA ANGELES FIGUEROLA SANTOS	CALLE DE MARIA DE MOLIA, NO. 54	PLANTA 8	MADRID		28006	ES
28619519	SMC LTD.	ATTN: CONTRACT ADMINISTRATION	330 SMC DRIVE		SOMERSET	WI	54025	
28617063	SMC, LTD.	330 SMC DRIVE, ATTN: CONTRACT ADMINISTRATION			SOMERSET	WI	54025	
28618792	SMC, LTD.	PO BOX 1450			MINNEAPOLIS	MN	55485-5846	
28873172	SMITHKLINE BEECHAM CORPORATION	FIVE MOORE DRIVE			RESEARCH TRIANGLE PARK	NC	27709	
28873174	STERLINGRX	ATTN: GENERAL COUNSEL	1312 NORTHLAND DRIVE, SUITE 500		MENDOTA HEIGHTS	MN	55120	

Exhibit C
Assumption Counterparties Service List
Served via overnight mail

AddressID	Name	Address1	Address2	Address3	City	State	Postal Code	Country
28617151	STERLINGRX, INC.	1312 NORTHLAND DRIVE, SUITE 500, ATTN: GENERAL COUNSEL			MENDOTA HEIGHTS	MN	55120	
28617070	SUN PHARMACEUTICALS INDUSTRIES LIMITED	ATTN: MR. KIRTI GANORKAR, SENIOR VICE PRESIDENT	SUN HOUSE, 201/B1 WESTERN EXPRESS HIGHWAY GOREGAON		MUMBAI, MAHARASHTRA		400064	IN
28873178	THE F. DOHMEN CO.	24740 NETWORK PLACE			CHICAGO	IL	60673-1247	
28873179	THE F. DOHMEN CO. (D/B/A MEDCOMM SOLUTIONS)	24740 NETWORK PLACE			CHICAGO	IL	60673-1247	
28873181	THE HIBBERT COMPANY INC. D/B/A THE HIBBERT GROUP	LBX 41765 PO BOX 8500			PHILADELPHIA	PA	19178	
28873182	THE HIBBERT GROUP	ATTN: OKSANA POSEWA	400 PENNINGTON AVENUE		TRENTON	NJ	08618	
28873183	THE HIBBERT GROUP	LBX 41765 PO BOX 8500			PHILADELPHIA	PA	19178	
28617087	TRIALCARD INCORPORATED	ADDRESS ON FILE						
28618875	TRIALCARD INCORPORATED	PO BOX 745577			ATLANTA	GA	30374-5580	
28873185	UNIVERSITY OF WISCONSIN HOSPITALS AND CLINICS	ATTN: UWHC ACCTS PAYABLE	PO BOX 5448		MADISON	WI	53705-5448	
28873184	UNIVERSITY OF WISCONSIN HOSPITALS AND CLINICS	PO BOX 5448			MADISON	WI	53705	
28873115	VANESSE, BRENDA	ADDRESS ON FILE						
28617098	WALGREEN CO.	102 WILMOT ROAD, ATTN: SPECIALTY PHARMACEUTICAL DEVELOPMENT			DEERFIELD	IL	60015	
28873187	WALGREENS SPECIALTY PHARMACY, L.L.C.	PO BOX 650974			DALLAS	TX	75265-0974	
28873163	WEINBERGER, RACHEL	ADDRESS ON FILE						
28618947	ZINC HEALTH SERVICES, LLC	2211 SANDERS ROAD, ATTN: DIRECTOR, INDUSTRY ANALYSIS			NORTHBROOK	IL	60062	
28873177	ZURNDORFER, SUSAN	ADDRESS ON FILE						